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ABSTRACT 
Risk for Lung or Liver Metastasis in Women with Metastatic Breast Cancer 
Nathalie Horowicz-Mehler 
 
Metastasis is the most fearsome aspect of breast cancer (BC) a common disease in 
women, because it drives mortality. Although BC can invade almost any organ, it is most often 
found to invade the bone (31-79%), the brain (3-12%), the liver (8-18%) and the lung (11-13%). 
The site of distant metastasis is often associated with cause of death and length of survival. This 
dissertation examines whether the presence of select lifestyle and clinical factors can predict 
metastatic spread to the lung and/or the liver for a particular woman with advanced breast cancer.  
A systematic review of the literature identified tobacco use as a risk factor for lung 
metastasis in women with BC and suggested that obesity, hormone replacement therapy prior to 
BC diagnosis, hormonal therapy post diagnosis, and post-mastectomy radiation therapy may 
have an impact on this association. The review also uncovered that liver disease (i.e. hepatic 
steatosis, chronic hepatitis B infection, cirrhosis) is associated with the occurrence of liver 
metastasis in patients with colorectal cancer and that hyperglycemic and oxidative stress 
conditions as well as alcohol consumption were found to be associated with liver metastasis in 
colorectal or BC patients.  
We conducted a retrospective hospital-based case-control study of the association of 
select lifestyle and clinical factors with metastases detected in the lung and the liver among 
women diagnosed with stages II-IV BC and seen at the Columbia University Medical Center 
from 2008 to 2013. Select relevant clinical variables were extracted from the hospital patient 
charts and lifestyle factors from patients’ responses to a questionnaire developed for the purposes 
of this research.  
We examined whether smoking and / or post-mastectomy radiation therapy to the breast 
and/or the chest area were associated with an increased risk of 1st site lung metastasis in our 
sample of women with metastatic BC. We found that lifestyle factors such as smoking history or 
BMI at diagnosis did not affect the likelihood of 1st site lung metastasis in our sample of women. 
We also investigated whether a history of alcohol intake or chronic liver disease was associated 
with risk of developing a 1st site liver metastasis. Our analyses suggested that lifestyle factors 
such as alcohol intake or obesity might not affect the likelihood of 1st site liver metastasis in 
women with metastatic BC. We also report that a history of chronic liver disease significantly 
increased the odds of 1st site liver metastasis.  
Given our findings around adjuvant post mastectomy radiation therapy and chronic liver 
disease, we suggest collecting adjuvant treatment or relevant comorbid information in larger 
cohort studies. A better understanding of the relationship between these factors and the sites of 
metastasis has the potential to increase our understanding of the metastatic process. If we can 
find ways to identify women at high risk of metastatic disease, or develop preventive or 
therapeutic measures against lung or liver metastasis, we can hope to reduce mortality from 
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 It is estimated that in 2015, in the United States, 234,190  individuals (231,840 female, 
2,350 male) will be diagnosed with breast cancer (BC) and that 40,730 patients (40,290 female, 
440 male) will die from the disease.1  BC is the most common cancer in women in the United 
States; an estimated 12.32% women will be diagnosed in their lifetime.2  Metastasis, the spread 
of cancer from the primary tumor site to other parts of the body, is the most fearsome aspect of 
this disease because it drives mortality. The 5-year relative survival is 98.6% for patients with 
localized BC, and 84.9% for those with regional BC, but only 25.9% for those with metastatic 
BC.1  Although only 5% of patients have apparent metastases at the time of diagnosis, 11% of 
women diagnosed at stage II and 13% of those diagnosed at stage III will develop a recurrence or 
metastasis within five years after they start systemic therapy.3  The potential of a cancer to 
metastasize depends on its interactions with homeostatic factors4 that promote tumor growth, 
survival, angiogenesis, invasion and metastasis in a distant ‘host’ organ.  
 Although BC can invade almost any organ, distant metastases are most often found in the 
bone (31-79%), the brain (3-12%), the liver (8-18%) and the lung (11-13%).5,6 Liver and lung as 
sites of metastasis were found to be significant predictors of poor survival following the first 
metastatic occurrence.7  Therefore the identification of factors associated with the risk of 
metastasis to a particular tissue or organ has the potential to improve treatment and survival.5 If 
we can learn what roles lifestyle and clinical factors play in the metastatic process, we may be 
able to identify high-risk patients, and to develop public health interventions addressing 
modifiable risk factors. The purpose of this systematic review is to evaluate what is known about 
the association of select lifestyle (smoking, alcohol consumption) and clinical factors (diabetes, 
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post-mastectomy radiation therapy, body mass index) with site-specific metastases, specifically 
those detected in the lung and the liver.  
Methods 
 The database of the National Center for Biotechnology Information at the U.S. National 
Library of Medicine itemizes articles from peer-reviewed journals and can be searched by 
medical subject heading (MeSH) terms, minor subject terms, and keywords.   We limited our 
search to literature published in English between January 1, 1990 and September 12, 2014. The 
full search strategies, including the specific search terms, are shown in Table 1. We excluded 
review articles and articles that did not directly address the associations of the specified 
exposures with lung or liver metastasis in BC. We did, however, include articles on the 
association of radiotherapy with lung carcinoma (LC) and articles on liver metastasis subsequent 
to colorectal adenocarcinoma (CRC). Indeed, the literature on liver metastases among patients 
with primary BC is sparse. Since metastatic liver disease is common in advanced CRC with 95% 
of patients dying with CRC found to have liver metastases,8  we considered that CRC studies 
might help us to develop hypotheses about factors that might be associated with metastasis to the 
liver in women with BC. The flowchart of the screening process from titles to final articles 
included in the review is shown in Figure 1.  
A search of PubMed with the MeSH terms and keywords identified 357 article titles, of 
which 10 proved to be duplicates. Of the remaining 347 articles, 288 were excluded based on 
titles that: 1) made no reference to liver or lung metastases; 2) made no reference to the effect of 
BC radiotherapy on smoking and lung disease; 3) focused on risk of BC, survival or patterns of 
recurrence, and not on metastasis; or 4) indicated not original research but editorials, interviews, 
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news reports, or reviews. A review of the abstracts of the remaining 60 articles led to the 
removal of an additional 43 articles due to either 1) lack of focus on associations between the 
exposures and outcomes of interest, or 2) focus only on the treatment or detection of metastasis. 
An additional 7 papers were identified through the review of relevant referenced articles. The 
full texts of the remaining 24 (17 plus 7) papers were reviewed for inclusion in the qualitative 
analysis; of those, 6 were removed because the full text article was not in English, did not focus 
on risk of lung or liver metastasis after exposure to risk factors, or focused on the treatment or 
detection of metastasis.  
From each of the remaining 18 articles, information was extracted on study design and 
date of publication, on the population studied (e.g., selection criteria, primary diagnosis, subject 
characteristics), on the exposure variable and method of measurement, on the metastatic 
outcome, on the type of analysis and confounders measured and adjusted for, and finally, on the 
association of the exposure with a site of metastasis, including measure of effect, and time from 
exposure to outcome. The information that was extracted is summarized in Table 2.   
Results 
Lung metastases   
We classified the 10 articles about factors associated with  lung metastasis from BC in 
four groups: 1) three articles describing the association of cigarette smoking with lung metastasis 
in BC; 2) two describing the role of obesity in the association of smoking and lung metastasis in 
BC; 3) two studying the association of hormone exposures (HRT or hormonal therapy) with liver 
and lung metastasis in BC; and 4) four on the joint effects of post-mastectomy radiation therapy 
(PMRT) for BC and smoking on the risk of developing second lung primaries.  
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We found strong associations between smoking and lung metastasis following BC 
(Table 3a) in both case control and cohort studies and after adjusting for confounding factors. In 
a case-control study of 87 women with unilateral invasive BC and lung metastasis,9 women with 
lung metastasis were twice as likely to report active cigarette smoking at diagnosis compared to 
women without lung metastasis (OR=2.26, p=0.05) after adjusting for hormonal therapy, 
presence of other sites of metastasis, tumor size and nodal status. In a retrospective follow-up 
cohort study of 835 women with unilateral BC,10 a significantly higher frequency of lung 
metastasis was observed in former (14.1%) or current (14.3%) smokers at diagnosis compared to 
non-smokers (8.7%) (p<0.01 smokers vs. non-smokers). In women with lung metastasis, 
cigarette smoking was associated with a shorter time interval between BC diagnosis and 
detection of lung metastasis (women with metastatic sites other than the lung were not studied). 
Specifically, mean time to discovery of lung metastases was 3.4 years (95% CI, 1.98-4.84); 3.2 
years (95% CI, 1.98-4.42) and 4.7 years (95% CI, 2.97-6.43) for current, former and 
nonsmokers, respectively. Additionally, a dose-dependent relationship was observed between the 
total packs of cigarettes smoked in a lifetime and the development of lung metastasis. Indeed, 
after adjusting for age, body weight and stage, the estimated relative risk of developing lung 
metastasis was nearly four times greater for a person who smoked more than 20,000 packs of 
cigarettes in their lifetime compared to a person who never smoked (RR=3.73 (95% CI, 1.58-
8.92) vs. RR=1.06 (95% CI, 0.51-2.2). We also found evidence from an experimental mouse 
study that tobacco increases the number of pulmonary metastasis with increasing degrees of 
smoke exposure, specifically mice exposed to tobacco smoke developed a greater mean 
metastatic burden in the lungs than unexposed animals.11  
6 
 
We found associations between obesity and larger axillary metastases and well as with a 
biomarker of smoking-related lung inflammation in women with BC (Table 3b). In a 
retrospective cross-sectional chart and tissue specimen analysis of 176 women with node-
positive BC, obesity (p=0.0002) and smoking (p=0.02) were significantly and independently 
associated with larger axillary metastases.12 In a study of 200 women with advanced BC with or 
without lung metastasis and 200 controls with early BC, significant positive associations 
between PGE-M levels (i.e. urinary metabolite of prostaglandin E2, a marker of smoking-related 
lung inflammation) and elevated BMI (p<0.001), older age (p<0.001), pack-year of smoking 
(p=0.02), receipt of cytotoxic chemotherapy within the last month (p=0.03) and lung metastasis 
regardless of liver metastasis status (p=0.02) were reported. Finally, elevated BMI was 
associated with increased lung metastasis (p=0.03).13  
Two papers describe associations of pulmonary and liver metastases in women with BC 
with adjuvant hormonal therapy (e.g., tamoxifen or oophorectomy) which blocks estrogen’s 
effects on the breast as well as hormone replacement therapy (HRT) provided prior to BC 
diagnosis, which increases hormone levels (Table 3c). A chart review study with 73.2 months of 
follow-up found that 473 women who had not received HRT prior to BC diagnosis (HRT-) had 
significantly more lung and liver metastases than the 320 who had received HRT (HRT+) (9.9% 
vs. 4.1%, p<0.001 for both sites).14  In a case-control study of 87 women with unilateral, 
invasive BC, fewer women with lung metastases had received adjuvant hormonal therapy than 
women without lung metastasis (23.3% vs. 42.8%, p<0.05).9  
Table 3d  summarizes the findings of papers describing the synergistic effect of post-
mastectomy radiation therapy (PMRT) and smoking on the risk of second lung primary 
following BC, especially in the ipsilateral lung. In a case-control study of 280 women with BC 
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and subsequent lung carcinoma and 300 matched controls (women with BC but no second 
primary to the lung, matched by age, ethnicity and year of diagnosis and survival from BC 
diagnosis to lung carcinoma diagnosis),15 smoking but not PMRT was found to be an 
independent risk factor for developing lung carcinoma (ORsmoking=5.6; 95% CI, 2.9-10.5; 
ORPMRT=0.6; 95% CI, 0.3-1.4) even after adjusting for BC histology, type of surgery, date of BC 
diagnosis, age, and ethnicity. A marked increase in the risk of lung carcinoma was observed 
among the women who smoked and received PMRT (adjusted OR=8.6, p=0.08).  Another case 
control study looking at the risk of second lung primary in 89 women with BC diagnosed with a 
subsequent lung cancer and 580 controls with BC and a second non-lung malignancy16 reported 
higher risk of lung cancer in non-smokers who had received PMRT (OR=3.2; 95% CI, 0.6-17.4), 
smokers who did not receive PMRT (OR=14.5; 95%CI 4.0-53.8), and and smokers who had 
received PMRT (OR=32.7; 95% CI, 6.9-154), than among on-smokers who had not received 
PMRT, especially on the ipsilateral lung (ORipsilateral=76.6; 95% CI, 8.1-724 and 
ORcontralateral=7.7; 95% CI, 0.8-71.9). In a case-only design (i.e., each woman contributed a pair of 
lungs) looking at 182 women with BC and a second lung primary,17 the mean latency period 
from primary diagnosis to  second lung primary in women without PMRT was 9.7 years with no 
difference between ipsilateral and contralateral outcomes. In women treated with PMRT, the 
mean latency increased for both ipsilateral and contralateral lung cancers (latencyipsilateral=17.6 
years, latencycontralateral=13.0 years). In women who received PMRT, the risk of developing 
ipsilateral lung cancer was higher than the risk of contralateral lung cancer more than 10 years 
after BC diagnosis (RR=2.04; 95% CI, 1.24-3.36). In a population-based nested case control 
study of 113 women diagnosed with non-metastatic BC who developed a second lung primary 10 
years after BC diagnosis and 364 controls (matched for age, year of BC diagnosis and length of 
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survival),18 ever-smokers who did not receive PMRT had an elevated risk of lung cancer (OR = 
5.9; 95% CI, 2.7-12.8) so did ever-smokers who received PMRT (OR=18.9, 95% CI, 7.9-45.4) 
compared to nonsmokers whether or not they received PMRT. The elevated risk of lung cancer 
was reported in both the contralateral (OR=10.5, 95% CI, 2.9-37.8) and ipsilateral lungs 
(OR=37.6; 95% CI, 10.2-139.0). 
 
Liver metastases 
 We reviewed the literature on liver metastases in CRC because the literature on liver 
metastases in BC is sparse, and we thought that studying the patterns in CRC might help to 
generate hypotheses regarding the role of lifestyle factors and clinical variables in metastasis to 
the liver among BC patients. Liver metastases are common among patients with advanced CRC. 
In fact, 95% of patients dying with CRC were found to have liver metastases.8  
The 8 articles about factors associated with liver metastasis fell into four categories: 1) 
Two articles about the association of hepatitis with liver metastasis in CRC patients; 2) two 
about the association of cirrhosis with liver metastasis in CRC patients; 3) three about the 
association of diabetes with liver metastasis in patients with CRC or BC; and 4) one about the 
association of alcohol intake with liver metastasis in patients with CRC.  
Table 4a presents findings on the association between hepatic steatosis or chronic 
HBV infection and liver metastases in CRC patients. A case-control study of 604 colorectal 
cancer patients who had undergone curative resection including metastectomy19 found that 
metachronous and synchronous liver metastases were found in a higher proportion of controls 
with normal livers than of cases with hepatic steatosis (metachronous: 12.1% vs. 1.7%, p=0.004; 
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synchronous: 9.6% vs. 3.2%, p=0.06). Hepatic steatosis was significantly associated with 
elevated liver enzymes (AST, ALT, and GGT, p=0.002) and with better survival (p=0.04).   
Five-year recurrence-free survival (RFS) was higher in patients with hepatic steatosis than in 
controls (82.1% vs. 68.1%), but the association was limited to intrahepatic metastasis; cases and 
controls did not differ in 5-year RFS with extrahepatic distant metastasis. Finally, among obese 
CRC patients, hepatic steatosis was not associated with RFS (p=0.44), and within the hepatic 
steatosis group, patients with no liver damage had better RFS than those with liver damage. In 
yet another case control study of 512 patients with CRC and resection,20  the incidence of liver 
metastases was lower in patients with HBV infection (13.5%) than in controls (13.5% vs. 27.1%, 
p<0.05). However, among HBV-infected patients, the risk of liver metastasis was similar in 
those with and without chronic liver damage. The rate of liver metastasis in patients with non-
replicative HBV infection (19.6%) was comparable to that of the HBV- group (27.2%; P = 0.05).  
 Two papers described the association between cirrhosis and liver metastases in CRC 
patients (Table 4b). A retrospective clinical chart analysis of patients with CRC and confirmed 
liver cirrhosis at the time of resection, found that liver metastases were relatively infrequent 
(~10%) in patients with cirrhotic livers followed for nearly 4 years.21 In another study, 16% 
(40/250) of patients with CRC developed hepatic metastases within 5 years of diagnosis, yet none 
(0%) of these patients had cirrhosis at diagnosis vs. 21.9% (46 of 210) of the patients who did not 
develop metastases (p<0.001).22  
 Three laboratory studies reported on the association between hyperglycemic conditions 
or oxidative stress and liver metastasis in CRC or BC models (Table 4c). Two in vitro mouse 
studies23,24 reported that hyperglycemic conditions induced angiotensin-II (A-II) activation in 
CRC cells in a dose-dependent manner and enhanced size and number of liver metastases. 
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Significantly fewer liver metastases were found in anti-angiotensin treated mice compared to 
untreated mice (p<0.001). An examination of 121 CRC patients24 showed that primary tumor A-II 
concentration was higher in patients with diabetes than in non-diabetics (p<0.05), and that A-II 
activation was positively associated with an increased number and size of liver metastatic nodules. 
In 107 T2DM case patients with BC, 25  lipid alteration under conditions of oxidative stress 
(hypochlorite-oxidized HDL), was associated with an increased number of metastatic nodules in 
the lung (164.3%, p<0.01) and liver (1840%, p<0.001) in vivo when compared to cells of 102 
nondiabetic controls. 
 Only one paper looking at the association between alcohol consumption and liver 
metastasis in patients with CRC met our criteria and was included in our review (Table 4d). 
Among 133 CRC patients with invasion beyond the submucosal layer who underwent resection,26 
the risk ratio for liver metastasis among alcohol users vs. non-users was 2.57 (95% CI, 1.43-4.36), 
but risk was not associated with amounts of alcohol consumed (average 51.7 ± 43.6 g/day), nor 
did any of the patients appear to have “serious liver injury” (patients with cirrhosis or alcoholic 
hepatitis were excluded). Alcohol consumption was significantly correlated with synchronous 




A positive association between smoking and lung metastasis in women with BC was 
observed across study designs. Two observational studies in women with unilateral BC found a 
significant dose-dependent association between a history of cigarette smoking and the 
11 
 
development of lung metastasis. History of smoking cigarettes was also associated with a shorter 
time interval between BC diagnosis and lung metastasis detection. The positive association 
between exposure to tobacco smoke and mean metastatic lung metastases was corroborated by a 
mouse study. Furthermore, in a case-control study of patients with esophageal cancer, smoking 
was associated with metastases to the lung (OR = 1.89; 95% CI, 0.80-4.46) but not to the liver 
(OR = 0.88; 95% CI, 0.42-1.83) potentially indicating that smoking has a site-specific effect.27  
However, the systemic effect of smoking on BC metastasis must be accounted for alongside 
specific effects on the lung. In a case control study, 72.4% of BC patients who smoked had 
metastatic disease involving sites other than the lung (mostly bone and liver) compared to 31% 
of non-smoking patients.9  
Obesity was associated with larger axillary metastases and an increased number of lung 
metastases as well as with a biomarker of smoking-related lung inflammation in women with 
BC.  Elevated levels of lung inflammation as evidenced by elevated urinary PGE-M levels 
appear to be a potential mediator of the relationship.13 The rapid development of pulmonary 
metastases in obese and diabetic mice injected with lung cancer and melanoma cells supports the 
association we observed in women with BC.28 Obesity is recognized as oncogenic and has been 
linked to increased incidence, morbidity and mortality from several types of neoplastic diseases 
including postmenopausal BC. However, prior studies of the relationship between smoking and 
lung metastasis have not always collected data on or accounted for the role of BMI or obesity in 
the association. Its association with both exposure and disease confirms the need to assess the 
impact of obesity on the relationship between smoking and lung metastasis.  
While women who were provided additional hormones before BC diagnosis for at least 1 
year (i.e. HRT) exhibited fewer metastasis to the lung or liver; women who were provided 
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adjuvant hormonal therapy after BC diagnosis to block hormonal effect to the breast and reduce 
risk of recurrence, did see a reduction in lung and liver metastasis as intended.  The authors of 
one of the papers9 speculated that hormonal therapy might not have been offered to, or might 
have been refused by, women who smoked because of the increased risk of thrombosis 
associated with both smoking and the use of tamoxifen. However, they did not study the 
association between smoking status and hormonal therapy and the potentially confounding 
effects of socio-economic status, health awareness. The apparent contradictory results should be 
investigated further along with the association between smoking status and adjuvant hormonal 
therapy and the potentially confounding effects of socio-economic status and health awareness.  
An independent association between smoking and an increased risk of second primary 
lung cancer in women with BC has been reported in the literature, this risk is sharply increased in 
smokers who received PMRT after BC diagnosis, especially in the ipsilateral lung. This elevated 
risk was reported 10 or more years after BC diagnosis and PMRT treatment, with a higher mean 
latency of ipsilateral lung cancers over contralateral lung cancers. The effect of PMRT on lung 
metastasis in women with BC has not yet been evaluated. However, there is evidence around the 
impact on irradiation on metastatic disease. In mice, irradiation of the lungs with 1000-3000 cGy 
of gamma rays before the intravenous injection of fibrosarcoma cells immediately increases the 
number of lung nodules.29  Another pre-clinical study found that tumors growing in irradiated 
tissues had a greater propensity to metastasize than those in un-irradiated tissues.30 Finally, there 
are case reports of tumor recurrence at previously irradiated skin sites31 and clinical evidence that 
lung metastases are more likely to occur on the side of the breast irradiated post-mastectomy 




Hepatic steatosis or chronic hepatitis B in patients with CRC appears to have a protective 
effect on the occurrence of liver metastasis. Hepatic steatosis was associated with improved risk-
free survival and a decrease in the number of intrahepatic metastasis, and this association was 
observed only in non-obese patients. In CRC patients with hepatic steatosis and chronic HBV, 
liver damage had no impact on the association. Epidemiologic findings suggest that CRC rarely 
metastasizes to the cirrhotic liver. A study of 72 patients with liver metastases at time of 
resection indicates that while a significant association was found with evidence of fatty liver, the 
protective effect on liver metastasis is stronger with further liver damage, such as cirrhosis.33 
Liver pathology is correlated with elevated liver enzymes (i.e. AST, ALT and GGT).34  When 
studying the association between liver pathology and the likelihood of liver metastasis, we will 
consider diagnosis of liver pathology as well as the presence of associated elevated liver 
enzymes as a proxy for the presence of liver damage, whose association with reduced risk of 
liver metastasis following CRC diagnosis remains unclear. 
 Hyperglycemic conditions may lead to A-II activation in CRC cells and to an increase in 
the size and number of liver metastases. Lipid alteration under conditions of oxidative stress is 
similarly associated with an increased number of metastatic nodules in the lung and liver in vivo 
BC models. T2DM and hyperlipidemia have been associated with both fatty liver and non-
alcoholic steatohepatitis (NASH).35 Several recent studies also indicate that diabetic patients 
have a higher prevalence and greater severity of liver disease when compared to non-
diabetics.36,37  Alcohol consumption was found to be a significant and independent risk factor for 
liver metastasis in CRC patients, especially with synchronous liver metastasis. Carmofur, a 




The chapters that follow will address under-investigated aspects of research on risk 
factors for lung and liver metastases among patients with BC.  In chapter 2, we will consider the 
relationship between smoking and development of lung metastasis in women with BC; we have 
systematically collected patient-reported smoking history to avoid the proxy data and 
inaccuracies that have plagued prior studies9 but also decrease missing data for the main 
exposure.27 We also propose to assess the role of obesity/BMI, PMRT, and adjuvant hormonal 
therapy or hormone replacement therapy in the association between smoking and lung as well as 
in the association of smoking with non-lung metastasis. Chapter 3 will investigate the 
relationship between liver pathology and risk factors associated with liver damage (e.g., alcohol, 
diabetes, HBV) in women with advanced BC. Time from initial BC diagnosis to evidence of 
liver metastases has been found to be 13-168 months (median: 83 months);39 thus a prospective 
study in BC patients would require a very large sample and lengthy follow-up. We will 
comprehensively assess liver damage history as well as clinical proxies, such as liver enzymes in 
a retrospective chart study; and will consider time from BC diagnosis to liver metastasis as well 









Table 1: Search Terms Used to Identify Relevant Articles for the Systematic Literature Review  
Search Aim Search Strategy Records 
Smoking as a Risk 
Factor for Lung 
Metastases 
("breast cancer"[ti] OR (breast[ti] AND cancer[ti]) OR (breast[ti] AND carcinoma[ti]) OR mastectomy*[ti])) AND 
(risk OR damag* OR advers* OR associat* OR caus* OR correlate*) AND (Lung Neoplasms/etiology[mh] OR 
"secondary lung" OR "secondary cancer" OR “lung malignancy” OR “lung malignancies” OR “second lung” OR 
"Lung Neoplasms/secondary"[MAJR] OR (Lung Neoplasms[mh] AND (Neoplasms, Multiple Primary[mh] OR 
Neoplasms, Second Primary[mh]))) AND (Smoking/adverse effects[mh] OR Tobacco Smoke Pollution/adverse 
effects[mh] OR smoking/adverse effects[mh] OR "Tobacco Products/adverse effects"[Mesh] OR smoking OR 
smoker* OR tobacco) AND ("1990/01/01"[PDAT] : "2014/12/31"[PDAT]) NOT ("case reports"[ptyp] OR 
bronchogen* OR "primary lung")  
30 titles  
Radiotherapy as a 
Risk Factor for 
Lung Metastases 
("breast cancer"[ti] OR (breast[ti] AND cancer[ti]) OR (breast[ti] AND carcinoma[ti]) OR mastectomy*[ti])) AND 
(risk OR damag* OR advers* OR associat* OR caus* OR correlate*) AND (Lung Neoplasms/etiology[mh] OR 
"secondary lung" OR "secondary cancer" OR “lung malignancy” OR “lung malignancies” OR “second lung” OR 
"Lung Neoplasms/secondary"[MAJR] OR (Lung Neoplasms[mh] AND (Neoplasms, Multiple Primary[mh] OR 
Neoplasms, Second Primary[mh]))) AND (Radiation Tolerance[mh] OR radiation effects[mh] OR radiation 
genetics[mh] OR Radiation Injuries[mh] OR "Radiotherapy/adverse effects"[Mesh] OR radiotherap*[ti] OR 
radiation[tiab] OR radiotherapy[tiab] OR radiotherapy[sh] OR radiation effects[sh] OR Dose-Response Relationship, 
Radiation[mh]) AND ("1990/01/01"[PDAT] : "2014/12/31"[PDAT]) NOT ("case reports"[ptyp] OR bronchogen* 
OR "primary lung")  
59 titles  
Overweight/Obesity 
as a Risk Factor for 
Lung Metastases 
("Hyperlipidemias"[Mesh]) OR "Body Mass Index"[Mesh] OR diabet*[tiab] OR obes*[tiab] OR overweight[tiab] 
OR "Overweight"[Mesh] OR "Diabetes Mellitus"[Mesh] OR bmi[ti] OR hyperlipidemi*[tiab]) AND 
("Smoking"[Mesh]) OR "Tobacco Smoke Pollution"[Mesh] OR "Tobacco Products"[Mesh] OR "Tobacco"[Mesh] 
OR "Tobacco Use"[Mesh]  smoking[tiab] OR smoker*[tiab] OR tobacco[tiab]) AND (neoplasm*[ti] OR 
neoplasms[major] OR cancer*[ti] OR metastatic[ti] OR metastasis[ti] OR carcinoma*[ti]) AND obes*[ti] OR 
overweight[ti] AND risk* OR associat* OR correlat* OR caus* OR secondary OR prevalen* OR inciden* OR 
epidemiolog* OR Epidemiologic Methods[mh] NOT ("Editorial" [Publication Type] OR "Review" [Publication 







smoking as Risk 
Factors for Liver 
Metastases 
(Liver Neoplasms/secondary[mh] OR "liver metastasis" OR "liver metastases" OR (Neoplasm Invasiveness[mh] 
AND liver) OR (Neoplasm metastasis[mh] AND liver)) OR liver/pathology[mh] OR liver/physiopathology[mh] OR 
"liver pathology" OR "pathological livers" OR "pathological liver" OR Liver Cirrhosis[mh] OR 
liver/enzymology[mh] OR “liver disease” OR hepatic[tiab] OR “secondary liver”) AND ("Breast 
Neoplasms"[Major] OR "Colorectal Neoplasms"[Major]) OR ((colon*[ti] OR breast[ti]) AND (cancer*[ti] OR 
carcinoma*[ti] OR neoplasm*[ti])) AND risk* OR associat* OR correlat* OR secondary OR epidemiolog* OR 
Epidemiologic Methods[mh] OR predict* AND  ("Hyperlipidemias"[Mesh]) OR "Body Mass Index"[Mesh]) OR 
"Overweight"[Mesh] OR obesity[mh] OR "Ethanol"[Mesh] OR "Alcohols"[Mesh] OR "Alcohol-Induced 









Table 2: Relevant Extracted Fields 
Domain Measures 
Study Identification & Design Author, Publication Date, Study Design 
Patient Population Selection Criteria, Primary Cancer Diagnosis, Subject Characteristics 
Exposure Exposure Definition, Exposure Measurement 
Outcome Metastatic Site and Measurement 
Analysis Variables Adjusted in the Analysis 
Impact of Exposure Impact of Exposure on Site of Metastasis 
 
  
Disorders"[Mesh] OR "Alcohol-Related Disorders"[Mesh] OR "Alcohol Drinking"[Mesh] OR "Diabetes 
Mellitus"[Mesh] OR "Smoking"[Mesh]) OR "Tobacco Smoke Pollution"[Mesh] OR "Tobacco Products"[Mesh] OR 
"Tobacco"[Mesh] OR "Tobacco Use"[Mesh] OR  hyperlipidemi*[tiab] OR alcohol[tiab] OR smoking[tiab] OR 
smoker*[tiab] OR diabet*[tiab] OR obes*[tiab] OR overweight[tiab] OR tobacco[tiab] OR bmi[tiab] OR “body mass 
index”[tiab]) NOT ("Editorial" [Publication Type] OR "Review" [Publication Type] OR "case reports"[ptyp] OR 

































BC between 1982 
and 1991 with lung 
metastasis (n=94) or 
no metastasis at f-up 
 
Women with non-
lung metastasis or 
with metastasis at 
time of Dx. were 
excluded  
Cigarette smoking 
history at BC 
diagnosis using a 
standardized 
questionnaire 
current smokers  
former smokers 
(stopped >2 yrs prior 
to Dx.)  
nonsmokers 
total lifetime pack of 
cigarette smoked 
Lung metastasis as found in hospital 
charts or medical records from private 
physicians 
regular checkup irrespective of smoking 
status every 6 months for the first 2 









adjusted RR for 
developing lung met 
(smokers vs. non) 






met-free time (years) 
4.7 nonsmokers 





Cases = 87 women 
with unilateral, 
invasive BC and 
lung metastasis  
 
matched controls 
(1:2) = without lung 
metastasis (matched 
for year of 
diagnosis, age at 
diagnosis, size of 
primary tumor, and 
nodal status) 
Cigarette smoking 
history obtained from 
medical charts  
ever-smokers active 
ever-smokers former  
never smokers 
number of pack-years 
 
1) pleural effusion with cytologic 
evidence of malignancy; (2) pleural 
effusion, exudative in character, without 
alternative explanation and attributed, in 
the medical record, to metastatic disease; 
(3) multiple pulmonary nodules on chest 
radiograph or CT scan interpreted by the 
clinician and radiologist to be metastatic 
in etiology, whether or not a biopsy was 
performed; and (4) a radiographic 
pattern on plain film or CT scan 
interpreted by the radiologist to be 
consistent with lymphangitic 
carcinomatosis. Patients with single-
mass lesions of the lung were excluded 
because of the potential for mis-












crude OR active 
smoking at diagnosis  
1.76, NS 
adjusted OR 
(hormonal Tx) 1.96 
(p=0.06)  
adjusted OR  
(hormonal Tx., other 
mets, T size, nodal 
































cAnN mice injected 
with mouse 
mammary tumor 
cells at 1/3 
concentrations 
(50,000, 100,000, or 
150,000 cells/100 L) 




cigarette smoking (1 
week prior to injection 
of tumor cells) vs. 
filtered air for control 
mice 
Three weeks after injection, the mice 
were killed, and pulmonary metastases 




The mean metastatic 
burden in the lungs 
was significantly 
greater for smoke-
exposed animals at 
each concentration 
of tumor cells, size 
of metastatic 
nodules was not 
significantly 
different for exposed 
vs. unexposed 
animals 











Exposure Definition, Measure 
Metastatic Site &  
Measurement 













specimens with ≥ 
6 lymph nodes 
Smoking habits  
smokers (n=63) (≥5 cigarette/day 




Obese (n=72) 20% or more over 
recommended weight (as listed in 
the Metropolitan Life Insurance 
Height-Weight Tables) 
Largest diameter of 
the largest 
metastasis (M)  
Primary tumor size 
(P) 





patient’s age, ER 
status, P and 
nodal status 
 
An independent association 
between M/P ratio and obesity 
(p=0.0002) and smoking 
(p=0.0268) and between M 
and obesity (p=0.0201) 
The associations were 
independent of tumor estrogen 

















Exposure Definition, Measure 
Metastatic Site &  
Measurement 
















Controls: 200 BC 
no met within 1 







3 months or 
corticosteroids 
within 4 weeks 
Urinary lung inflammation 
biomarker (PGE-M)  
 
Smoking exposure in pack years 
(ever [100+ cigarettes in lifetime, 
former not smoking for past 12 
months] or never) 
 
Confounders of PGE-M such as 
NSAID use and other chronic 
inflammatory conditions captured 
via questionnaire 
Lung metastases as 







Multivariate analysis: elevated 
PGE-M associated with  
obesity (p < 0.001) 
aging (P < 0.001) 
pack-year smoking (P=0.02) 
lung metastases (P=0.02) 
cytotoxic chemotherapy within 
1 month (p=0.03) 
 
Univariate: elevated PGE-M 
was positively associated with 
number of metastatic sites 
(p<0.001)  
 
Elevated BMI was associated 
with lung metastasis (p=0.03) 
 
receipt of NSAIDs within 7 
days was strongly associated 
with 
significantly lower levels of 















































HRT users= patients who had received 
preoperative HRT for at least 12 months 
(estrogen ± progestin) before surgery.  
HRT non users= patients who had not 
received any estrogen/progestin 
combination prior to BC diagnosis. 
Patients who received HRT for <12 
months included in the never-user group. 
Metastases localization 
and time to progression 
 
Metastases that 
occurred within the first 
6 months after the 
surgical procedure were 








Median follow-up = 73.2 
months 
HRT- vs. HRT+ women: 
More metastasis to  
the lung or the liver (9.9% 
vs. 4.1%, p<0.001 for each)  
more deaths (21.1% vs. 
7.5%, p<0.001) 



























a pair of 
lungs)  
182 women with 








via chart records 
 
29% had no 
smoking data in 
chart; data were 
collected by 
asking spouse or 
next of kin for 
information 
through a mailed 
survey 
Exposed lung = 
ipsilateral lung 
 





Mean dose of PMRT = 17.2 Gy (7.1-32.0)  
 
Women with PMRT, risk of developing lung cancer 
on ipsi vs contra > 10  yrs after BC Dx. (RR=2.04; 
95% CI, 1.24-3.36) 
smokers (RR= 3.17; 95% CI, 1.66 - 6.06) 
non-smokers (RR=0.9; 95% CI, 0.37-2.22) 
 
The mean latency period between BC and lung 
cancer 
No PMRT = 9.7 years 
With PMRT ipsi = 17.6 years  



































metastatic BC  
Cases (n=113) LC 
10 years after BC 
Dx.  
Controls (n=1364) 
matched on age, 
year of BC Dx., 


















cases slightly more likely than controls to have 
undergone PMRT 
cases five times as likely to have both undergone 
PMRT and smoked (P<0.0001). 
In nonsmokers, women who did not receive PMRT 
had no higher risk of LC than women who received 
PMRT. 
 
Increased risk in LC 
Ever smoking no PMRT OR = 5.9 [2.7;12.8] 
smoking and PMRT vs neither OR = 18.9 [7.9;45.4] 
Contralateral LC OR=10.5 [2.9;37.8]  





Cases: 280 BC 
women, all stages 
including DCIS (30-
89 years) with lung 
cancer ≥ 6 months 




women matched by 
age and stage at 
diagnosis and 
survival from BC to 
lung carcinoma 
diagnosis, no lung 
carcinoma 
Smoking and 




Smoking at BC 
diagnosis via # 
packs/day and 
total # years 
smoked (available 
for 93% of cases 











70.1% of cases (vs. 21.8% of control patients) were 
current smokers at the time BC diagnosis. 
 
Risk of developing lung carcinoma 
Smoking alone (OR, 6.0; 95% CI, 3.55–10.13) 
PMRT alone (OR=0.54, 95% CI, 0.26 –1.13) 
Smoking and PMRT vs neither (OR=9.0, 95% CI, 









woman with BC 




vs no) was 
available for 
cancer cases 
Of the 89 cases: 





Smoking increased risk of LC with and without 
PMRT   


























Impact of Exposure on Site of Metastasis 
Control (n=580) 
woman with BC 
diagnosed between 
1986-1989 with a 
second malignancy 




1986 and 1989. 




information on RT 
or smoking 
OR (PMRT + smoking vs neither) = 32.7 [6.9-154] 
Ipsi OR=76.6 [8.1-724], contra OR=7.7 [0.8-71.9] 
OR (no PMRT, smoking vs neither) = 14.5 [4.0-53. 
I] 
OR (PMRT, no smoking vs neither) = 3.2 [0.6-17.4]   









Exposure Definition & 
Measurement 
Metastatic 
Site &  
Measurement 
Type of Analysis 
& Variables 
Adjusted 






604 CRC patients with 
curative resection including 
metastasectomy 
63 patients with liver-
spleen attenuation ratio 
lower than 1.1 
classified as having 
hepatic steatosis (HS) 
 
Obesity (BMI > 25) 
 
Liver dysfunction =  
AST over 38 U/L,  
ALT over 36 U/L, 






Fisher’s exact and 
Student’s t test 
applied.  
significance 





hazard model  
 
HS was also significantly associated with 
elevated liver enzymes (p=0.002) 
Neoadjuvant chemoradiotherapy (CRT) did 
not affect incidence of HS (13.0 % vs. 10.2 
% in CRT vs. non-CRT cases, p=0.5).  
liver recurrence in 58/470 (12.1 %) patients 
without HS but 1/59 (1.7 %) patients with 
HS (p=0.004) 
the synchronous hepatic metastasis in 3.2% 
patients with HS compared to 9.6% 
patients with normal liver (p=0.06)  
no difference in the rates of extrahepatic 
distant metastasis between the two groups 
(2/61 vs. 
19/522 (3.2 % vs. 3.5 % )  
In non-obese patients, HS associated with a 
significantly better prognosis in the overall 
RFS (p=0.04). In obese patients, HS was 















Exposure Definition & 
Measurement 
Metastatic 
Site &  
Measurement 
Type of Analysis 
& Variables 
Adjusted 






512 CRC patients with 
resection 
Cases (n=74) with chronic 
HBV infection (28 with 
replication, 46 without) 
Controls (n=438) no HBV 
infection Cases with no liver 
damage (53) or with (21), 
HCV patients excluded 
HBV infection with or 
without replication 
 
Chronic liver damage 
including chronic active 
hepatitis and liver 
cirrhosis was clinically 
diagnosed according to 
results of serum 













by chi-square test 
or Student’s t test. 
Survival was 
analyzed by the 
Kaplan-Meier 
method, and the 
log rank test was 
applied for 
comparison of the 
survival curves 
The incidence of liver metastasis in the 
HBV infection group (13.5%) was lower 
than that of the noninfection group (27.1%, 
P= 0.05) 
 
HBV infected patients with and without 
chronic liver damage did not differ in risk 
of liver metastasis (P=0.05) 
liver metastatic rate of patients with 
nonreplicative HBV infection (19.6%) was 
comparable to that of the noninfection 
group (27.2%; P .0.05).  
 











Exposure Definition & 
Measurement 
Metastatic Site &  
Measurement 
Type of Analysis & 
Variables Adjusted 
Impact of Exposure on 







operated on for 
CRC and 40 
(56%) with 
confirmed liver 
cirrhosis at time 
of procedure 
Cirrhosis diagnosed by liver 
biopsy or by a history of liver 
disease via impaired liver 
function tests and CT scan or 
US. The surgeon had to 
confirm that the liver 
appearance was compatible 
with cirrhosis. Patients with 
steatohepatitis were excluded 










of developing liver 
metastases estimated 
using the Kaplan-Meier 
method, and curves were 
compared using the log-
rank test. 
median follow-up =46 
months 
N=7 (10%) patients 
presented with liver 
metastasis, n=3 presented 
with synchronous lesions at 
the time of colectomy, 
while n=4 others developed 


















Exposure Definition & 
Measurement 
Metastatic Site &  
Measurement 
Type of Analysis & 
Variables Adjusted 
Impact of Exposure on 








patients  with 
liver metastasis 
(40) or without 
metastasis (210) 
Hepatitis B surface antibody 
Liver cirrhosis based on lab 
values (total bilirubin 
≥1.5mg/dL and albumin 
≤3.5g/dL and GGT ≥46IU/L 
and cholesterolinase ≤3,500 
IU/L) and ICGR15≥15%) as 
well as histologic diagnosis by 
liver biopsy of surgical 
specimen 
Not described Chi-square test  
Liver cirrhosis was not 
found in the metastatic 
group but was present in 
21.9% in the non-
metastatic group (p<0.001) 
Prevalence of HB 
antibody-positive disease 
was 10% in the metastatic 




































CRC model  
 
Liver metastasis of 






sugar and serum 
A-II 
# and size of 






hyperglycemic condition induced A-II 
activation in CRC cells and enhanced liver 
metastasis of HT29 cells. In contrast, anti-
angiotensin treatment abrogated liver 
metastasis vs. that in hyperglycemic condition 
and even in control condition. 
 
In humans, The tumoral A-II concentration 
was higher in stage C and D patients with 
diabetes than that in nondiabetic patients 
(P\0.05) and showed that angiotensin 
activation is associated with the 
diabetic/hyperglycemic status of CRC patients 












107 patients with 
T2DM and 102 healthy 
controls 












After 20 days, 
lungs and livers 
were resected 




Student t test and 
ANOVA test 
D-HDL dramatically promoted cell pulmonary 
metastasis (103.6% increase at P < 0.001) and 
hepatic metastasis (18.1-fold increase at P < 
0.001) 
The nodules on the lungs of HDL groups 
increased by over 111.8% vs control (p < 0.05)  
the nodules on the livers of HDL groups 












mice were fed 
normal or high-
calorie diet with 




sugar and A-II in 
serum 
# and size of 
metastatic foci in 
the liver 
Mann-Whitney 
U test and the 
Kruskal-Wallis 





Increased concentrations of glucose led to 
dose-dependent increased levels of A-II 
High calorie diet, increase in blood glucose, 
increase in size and numbers of CT26 liver 
metastases.  
Fewer liver metastasis were found in anti-


















Exposure Definition & 
Measurement 
Metastatic 





















Patients who had 10g of 
alcohol daily before 
surgery were classified 
as alcohol-consuming. 
All other patients were 
nonalcohol-consuming 
10-30g of alcohol / day 
30–60 g / day 
60 g /day 
We performed 







Univariate analysis showed alcohol consumption 
(P=0.0021) was correlated with liver metastasis.  
Multivariate analysis showed alcohol to be 





















The above figure was adapted from Liberati et al. “The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of 
Studies that Evaluate Health Care Interventions: Explanation and Elaboration”.8 Once eligible articles were chosen, titles of articles 
cited in those papers were reviewed for potential inclusion.  
  
# of records identified through database 
searching: N = 357 
# of additional records identified by 
title through reviews of relevant 
articles  
N = 7 
# of records after duplicates removed  
N = 347 
# of records screened through title 
 N = 60 
288 records removed 
 
# of full-text articles assessed for 
eligibility 
N = 17+7 = 24 
6 full-text articles 
excluded 
# of studies included in qualitative 
synthesis 
N = 18 
# of records screened through abstracts   
 N = 17 
43 records removed 
 
# of additional records screened 
through abstracts 
N = 7 
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 Advanced breast cancer (BC) has a poor prognosis; 5-year relative survival among 
patients with metastatic breast cancer is 25.9%.1  Although in the United States only 5% of 
patients are diagnosed with apparent metastases, the risks of BC recurrence (including metastatic 
spread) within five years of the start of systemic therapy are 11% for women diagnosed at stage 
II and 13% for those diagnosed at stage III.2  The potential of a cancer cell to metastasize, or 
spread from the primary tumor site to other parts of the body is believed to depend on 
interactions with homeostatic factors3 that promote tumor growth, survival, angiogenesis, and 
invasion of a distant ‘host’ organ.  
 Although BC can invade almost any organ, metastases are most often found in the bone 
(31-79%), the brain (3-12%), the liver (8-18%) and the lung (11-13%).4,5 Metastases to liver and 
lung were found to be significant predictors of poor survival following the first metastatic 
occurrence.6 Therefore the identification of factors associated with the risk of metastasis to a 
particular tissue or organ has the potential to improve treatment and survival,4 to increase our 
understanding of the role lifestyle and clinical factors play in the metastatic process, to help 
identify high-risk patients to be targeted for treatment or prevention, and thus to inform public 
health intervention addressing modifiable risk factors.  
 An association between smoking and lung metastasis was observed in women with BC. 
In a case-control study published in 2001,7 the adjusted odds ratio for lung metastases among 
active smokers vs. nonsmokers among breast cancer patients was 1.96 (p=0.06). In a cohort 
study of women with BC,8 the adjusted relative risks for lung metastases in those smoking 
<10,000 packs, 10,001-20,000, and >20,000 packs over their lifetimes compared to nonsmokers 
were 1.06 (95% CI, 0.51-2.20), 3.10 (95% CI, 1.5-6.3), and 3.73 (95% CI, 1.6-8.9), respectively. 
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In addition, the time interval from BC diagnosis to the diagnosis of metastasis decreased from 
4.7 years for nonsmokers to 3.4 years for current smokers. An association between smoking and 
lung metastasis has also been observed in patients diagnosed with esophageal cancer (OR, 1.89; 
95% CI, 0.80-4.46).9 
 A marked increase in the risk of second primary lung cancer (as opposed to lung 
metastasis from a breast primary) was observed among women with BC who both smoked 
cigarettes and received post-mastectomy radiation therapy (PMRT) (OR=8.6).10,11,12 The 
association was observed only among smokers (RR = 3.08; 95% CI, 1.61 to 5.91). In another 
study by the same authors,13 the association of PMRT with second primary lung cancer in 
women with BC was also restricted to smokers (RR=3.2) versus non-smokers (RR=0.9).   
 We conducted a retrospective hospital-based case-control study of women with 
metastatic BC to assess whether smoking and / or adjuvant PMRT were associated with a higher 
risk of developing a lung metastasis than a non-lung metastasis among women with metastatic 
BC.   
Materials and Methods 
Study Site   
 The study was conducted at the Columbia University Medical Center (CUMC), an 
academic medical center in which 200-300 patients per year are diagnosed with BC. The 
ethnically and socioeconomically diverse patient population comes mainly from New York, New 
Jersey and Connecticut.  The study was approved by the CUMC Institutional Review Board, and 




 The sampling frame for the study was women who received treatment for metastatic BC 
at the CUMC between 2008 and 2013. Patient databases were screened to identify those with a) a 
histologically confirmed diagnosis of unilateral breast neoplasm with synchronous or 
metachronous metastasis; b) female gender; c) age at least 18 years; d) speaking Spanish or 
English; e) providing informed consent to participate in all aspects of the study; f) mentally 
competent as judged by medical study staff. For purposes of analysis, cases were defined as 
women diagnosed with metastasis to the lung as a 1st site of metastasis with or without metastasis 
to non-lung sites; metastasis was detected at diagnosis (prevalent or stage IV) or subsequent to 
diagnosis in stage I, II, or III (incident). Controls were women diagnosed with unilateral 
malignant breast neoplasm who had metastases at sites other than the lung, detected at or after 
breast cancer diagnosis. 
Study Recruitment  
 Study subjects were patients of providers in the breast oncology clinic or breast surgeons, 
who were identified from the patient logs by recruiters from CUMC’s Herbert Irving 
Comprehensive Cancer Center (HICCC) Community & Ambulatory Research & Enrollment 
(CARE) shared resource. A CARE recruiter contacted eligible patients in person, by phone or by 
mail prior to an office visit and invited them to participate in the HICCC Women with Breast 
Cancer Metastases (HICCC-WBCM) study. Three attempts were made to contact eligible 
patients by phone or mail before the patient was considered non-responsive.  
Data Collection 
 Questionnaire.  In the breast clinic, after obtaining informed consent, a trained 
interviewer administered the HICCC-WBCM questionnaire in a 60-minute face-to-face 
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interview in the participant’s preferred language (English or Spanish).  The following variables 
were collected for all women using the HICCC-WBCM questionnaire: 
Personal Smoking History: The HICCC-WBCM questionnaire provided around the time of BC 
diagnosis asked participants about their smoking history, specifically: “Are you currently a 
smoker?“, ”Did you ever smoke at least 1 cigarette per day for one month or longer?” and if 
relevant “Considering all the times you quit smoking, how many years have you smoked?” as 
well as “How many packs per day do/did you typically smoke?”, ”At what age did you stop 
smoking cigarettes?”. We quantified smoking history as pack/years and classified patients as 
current (smoking at or less than 2 years prior to BC diagnosis), former (ever smoked but stopped 
at least 2 years before BC diagnosis), or never smokers, as was done previously.8 We also 
considered a severe smoker classification that required at least 10 pack years of smoking. 
Body Mass Index (BMI): at age 35, 5 years prior to and at BC diagnosis both as a continuous 
variable and using the following categories: <18.5=underweight; 18.5-24.9=normal; 25-
29.9=overweight and >30=obese. 
 Record review.  Our HIPAA-certified research team collected data retrospectively from 
the patients’ records in the New York Presbyterian Hospital Electronic Medical Record (EMR) 
systems (WebCIS and CROWN), drawing on hospital admissions histories, imaging studies, 
laboratory data, pathology reports, and consultation notes. Some women died prior to the end of 
our study, others were lost to follow-up but chart data were collected for all women until the end 
of the data collection phase in December 2014.  
Breast Cancer: histologically confirmed diagnosis of unilateral malignant breast neoplasm.   In 
addition, all cases and controls studied had metastatic disease detected either at or after the time 
of the BC diagnosis. Like prior published studies of metastatic sites in women with BC7,8 ours 
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included only women with unilateral BC so that we could link the metastasis to a unique primary 
lesion and its distinct clinical characteristics. 
Post-Mastectomy Radiation Therapy (PMRT): Adjuvant radiation therapy administered after 
mastectomy and prior to the diagnosis of metastatic disease. Data collected on recipients of 
PMRT include date of last radiation therapy dose, total dose received at a given site (cGy), 
anatomical location of the radiation (e.g., breast or chest wall, left or right side) and side of the 
lung metastasis in relation to the side of PMRT 
Lung Metastasis: Patients were categorized as having lung metastases, detected either at 
diagnosis or during follow-up, based on radiologic findings of ≥2 suspicious nodules in the lung 
parenchyma or findings consistent with lymphangitic carcinomatosis, or cytologic confirmation, 
in a pleural effusion, of malignant cells consistent with the primary breast tumor histology. 
Biopsy confirmation of lung metastasis was recorded where possible to exclude second primary 
lung cancer as well as non-malignant clinical manifestations, as were date of metastatic finding, 
laterality, imaging consistent with emphysemic changes (i.e., atelectasis or bronchioectasis), and 
radiation pneumonitis or radiation fibrosis. As in other studies,7,9  we excluded patients with a 
single-mass lung lesion to avoid mislabeling a primary lung cancer as a BC lung metastasis. In 
another study, of 45 patients with BC (or another histologically similar cancer), 26 (58%) had 
solitary lung nodules but only 8 (18%) had primary lung cancer and 11 (24%) a benign lesion.14   
Site of first or subsequent metastasis: Imaging dates recorded in the medical chart, indicating 
when each metastasis was first suspected or detected, were compared. In some patients, work-up 
uncovered multiple metastatic sites; if 2 sites were detected within a 30-day period, we 
considered them to have occurred simultaneously. As a consequence, more than one site could 
have been considered as a first site of metastasis. 
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Follow-up time: time from BC diagnosis to death or last follow-up date due to study completion 
or loss to follow-up. Some women died and others were lost to follow-up prior to the end of our 
study, but chart data were collected for all women until the end of the data collection phase in 
December 2014.  
Other Data 
 The research team also collected data from the EMR on breast tumor characteristics (e.g., 
histology, TNM stage, grade, and molecular subtype (HER2, ER, PR)) and on breast cancer 
surgery, adjuvant chemotherapy and hormonal therapy. History of respiratory disease (e.g., 
bronchitis, emphysema, COPD, asthma) was collected from both the EMR and the HICCC-
WBCM questionnaire. 
Statistical Analysis 
Categorical variables were analyzed using chi-square or Fisher’s exact test. To assess 
linear trends in levels of categorical variables, the Mantel-Haenszel Chi-Square test statistic was 
utilized. Continuous variables were analyzed using two-sided Student’s t-tests.  
Multivariate logistic regression analyses were performed to look at the combined effect 
of smoking status (never, former, current) or pack-years of smoking with adjuvant PMRT as well 
as to adjust for the potential confounding effects of the participant’s age, race/ethnicity, stage of 
disease at time of BC diagnosis, body weight using BMI categories (normal, overweight and 
obese), other adjuvant therapies (i.e. hormone or chemotherapy), and respiratory disease history. 
Logistic regression was performed in the full sample of women diagnosed in stages I-IV. We 
also conducted a Kaplan-Meier survival analysis to assess the relationship between receipt of 
adjuvant PMRT and time from BC diagnosis to 1st site lung metastasis while accounting for 
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censoring (i.e., loss to follow-up, study end, or patient death). Survival analyses were restricted 
to women who were diagnosed at stages I-III because only women who were diagnosed at stages 
I-III had the opportunity to receive adjuvant PMRT. We used the log-rank test statistic to assess 
homogeneity of survival curves over strata of adjuvant PMRT status.  
Associations in which P<0.05 or the 95% confidence interval (95% CI) did not include 
the null value (1.00) were considered statistically significant. All analyses were performed using 
SAS statistical software, version 9.4; (SAS Institute; Cary, NC).  
Results 
Distribution and time to metastasis in our population 
We identified 183 women with histologically confirmed unilateral BC with metastases 
diagnosed with BC between 1977 and 2013. Figure 1 describes the selection process for the 
study population. Among these women, 133 (72.7%) were diagnosed with BC at stages I to III, 
and subsequently developed metastatic disease, while 50 (27.3%) were diagnosed at stage IV. 
More than half (n=102, 55.7%) developed lung metastasis, which was biopsy confirmed in 
36.3% of women. The lung was the first metastatic site for 70 women, 38.3% of the 183 
participants or 68.6%of the 102 women with a lung metastasis (Table 1). Of the 183 in the 
sample, 145 (79.2%) developed bone metastasis, 83 (45.4%) liver metastasis, and 66 (36.1%) 
brain metastasis. Only 46 women (25.1%) had a single metastatic site. Study participants were 
followed for an average of 8.1 ± 6.6 years. Mean follow-up time was somewhat shorter for cases 
(7.21 years) than controls (8.66 years), but the difference was not statistically significant 
(p=0.18). Women initially diagnosed in stages I-III were followed for a longer average period 
(9.8 ± 6.9 years) than women diagnosed in stage IV (3.4 ± 2.3 years).  Among the former, the 
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shortest time from diagnosis to first metastasis was for metastases to the lung (6.2 years) and the 
longest to the brain (7.5 years). 
Profile of women diagnosed with lung as 1st metastasis vs. women with non-lung metastasis 
The mean age of the 151 women included in the analysis (excluding 32 women who had 
lung metastasis as a 2nd or 3rd site) was 54.6 years; 82 (54.3%)were post-menopausal at 
diagnosis. A larger proportion of cases than of controls self-identified as Hispanic (42.9% vs. 
27.2%) while fewer self-identified as White (30.0% vs. 53.1%). Women with a 1st site lung 
metastasis (cases) were more likely to have been diagnosed in stages I-III as opposed to in stage 
IV compared to controls (78.9% vs. 61.8%, p=0.02). In terms of the breast tumor and treatment, 
a higher proportion of cases had invasive ductal carcinoma than had lobular carcinoma or 
another histological type (90.0% vs. 77.8%, p=0.04). However, cases did not differ from controls 
in differences in hormone receptor status. A larger proportion of cases than controls had a 
mastectomy as opposed to breast conserving surgery or no surgery (p=0.05), and a larger 
proportion received adjuvant chemotherapy (p=0.06). (Table 2) 
Neither BMI at diagnosis nor weight loss or weight gain within 5 years of BC diagnosis 
was associated with having a 1st site lung metastasis. About 30% of cases and 20% of controls 
had a diagnosis of type 2 diabetes mellitus but the difference was not statistically significant. 
(Table 2) 
Relationship between smoking history and lung as 1st metastasis in women with advanced BC 
Almost every participant (97.5%) provided data on her smoking status; 57.1% of cases 
vs. 56.8% of controls were never smokers (p=0.46). Although information on the smoking 
“dose” was incomplete or missing for some of the patients (15 out of 86 or 17.4% of smokers), 
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we assessed the distribution of pack-years of smoking and again found no difference between 
cases and controls (p=0.89) even after restricting analysis to ever smokers who had 10 or more 
pack years of smoking (p=0.31). An estimated 1/5th of the sample had a history of respiratory 
disease, specifically, asthma/COPD (13.2%), chronic cough/bronchitis (7.9%), emphysema 
(5.9%) or other conditions, such as tuberculosis or pneumonia, but cases did not differ from 
controls with respect to history of respiratory disease (p=0.72). (Table 2)  
We also compared ever and never smokers in the full sample by ethnicity, BC diagnosis 
and treatment variables, comorbidities, and site-specific metastasis. (Table 3a) A greater 
proportion of never smokers than of ever smokers were Hispanic (40.6% vs 26.8%), while a 
smaller proportion of never smokers than of ever smokers were White (32.7% vs. 52.4%). Never 
smokers were more likely to be diagnosed with BC at stages I-III than with a stage IV disease 
(78.2% vs. 65.8%, p=0.06).  There were no notable differences in the distribution of adjuvant 
treatment (p chemo = 0.80; p PMRT = 0.77; p Hormonal Therapy = 0.58) nor did we detect any difference 
across smoking groups with regard to receipt of HRT prior to BC diagnosis (p = 0.91).  
While ever and never smokers had similar BMIs at diagnosis (p BMI = 0.50), a larger 
proportion of ever smokers was found to have a 5% weight loss within 5 years of BC diagnosis, 
although the difference was not statistically significant (p=0.41). A larger proportion of ever than 
never smokers had a respiratory disease history (32.5% vs. 18.4%, p=0.03), but they did not 




Ever smokers did not differ from never smokers with respect to metastases to other sites 
(p liver = 0.72; p Bone = 0.72; p Brain = 0.42), mean time to site-specific metastasis, or time to any 
metastasis. (Table 3b) 
 The odds of getting a 1st site lung metastasis was not associated with smoking history 
(OR former = 1.15 [0.58;2.29]; OR current = 0.51 [0.15;1.79]), or pack-years of smoking (OR <20 = 
1.10 [0.51;2.34]; OR >20 = 0.86 [0.36;2.05]). In a multivariable logistic regression model, we 
found no interaction of smoking history and receipt of adjuvant PMRT therapy on odds of 1st site 
lung metastasis. Emulating two prior published studies, we adjusted for age, stage and BMI at 
BC diagnosis (“Scanlon, 1995 model”) but found no effect of pack years of smoking on odds of 
lung as 1st site metastasis (OR <20 = 1.14 [0.45;2.89]; OR >20 = 1.44 [0.49;4.20]); we also 
adjusted for adjuvant hormone therapy and other sites of metastasis (“Murin, 2001 model”), but 
again found no effect of smoking history on odds of lung as 1st site metastasis (OR former = 1.14 
[0.56;2.33]; OR current = 0.48 [0.13;1.75]). (Table 5) 
Relationship between adjuvant PMRT and lung as 1st metastasis in women with advanced BC 
In the study sample, the average time from BC diagnosis to end of PMRT treatment was 
8 ± 6.75 months for the 72 women for whom we had treatment end dates (22.6% of the women 
who received PMRT had missing or incomplete data). A significantly larger proportion of cases 
than controls received adjuvant PMRT (51.4% vs. 32.1%, p=0.02), and among women who 
received PMRT, those who developed a 1st site lung metastasis had received a higher mean 
radiation dose than those who developed a non-lung metastasis, but the difference was not 
statistically significant (4834 cGy vs. 3919 cGy, p=0.30). Of 17 women who had developed a 
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unilateral lung metastasis, 12 (70.6%) did so on the same side where they received PMRT (Table 
2).  
Among women diagnosed in stages I through III (Table 4), we found that a larger 
proportion of adjuvant PMRT recipients than non-recipients were White (39.7% vs. 30.9%), and 
a smaller proportion were Hispanic (29.5% vs.52.7%). Women who received adjuvant PMRT 
were also significantly more likely to have been treated with adjuvant chemotherapy (84.6% vs. 
60.0%, p=0.001) but just as likely as women who did not receive PMRT to be treated with 
adjuvant hormonal therapy (p = 0.96). Women who received PMRT were more likely to have 
evidence of respiratory disease (33.3% vs. 13.2%, p=0.01) and to be overweight (35.9% vs. 
27.6%, p = 0.07). Smoking history was similarly distributed across those who received PMRT 
and those who did not (p = 0.44).  
A larger proportion of women who received adjuvant PMRT developed lung metastasis 
than non-lung metastases (66.7% versus 50.9%, p=0.07). In fact, among women with a lung 
metastasis, those who received adjuvant PMRT were somewhat more likely to have lung as a 1st 
site of metastasis than those who did not receive PMRT (46.1% vs. 40.0%, p=0.03). Over 80% 
of both recipients and non-recipients of PMRT had multiple pulmonary nodules as their 
manifestation of pulmonary metastatic disease, and about 15% of both groups had lymphangitic 
carcinomatosis (p = 0.63); those categories were not mutually exclusive. Receipt of PMRT was 
not associated with non-lung metastases (i.e., liver, bone, or brain) (p=0.44; 0.88 and 0.54, 
respectively).  
In a multivariate logistic regression model, we found that women with metastatic BC who 
received adjuvant PMRT were more than twice as likely to have 1st site lung metastasis as 
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women who did not receive adjuvant PMRT (OR=2.24 [1.15;4.34]). The association remained 
statistically significant (OR=2.08 [1.06;4.08]) after adjusting for age at diagnosis and other 
adjuvant therapies (i.e. receipt of adjuvant chemotherapy and adjuvant hormone therapy) but not 
after adjusting for age at diagnosis and smoking history (OR=2.02 [0.84;4.83]). Other adjuvant 
therapies including chemotherapy and hormone therapy were not independent predictors of lung 
as 1st site of metastasis. (Table 5) 
Of 116 women diagnosed with stage I, II, or III breast cancer, 55 (47.4%) received 
PMRT.  Of those 55, 36 (65.5%) developed a 1st site lung metastasis, while of the 61 women 
who did not receive PMRT, 34 (55.7%) developed a 1st site lung metastasis.  In a survival 
analysis, the receipt of PMRT was not associated with significantly different lead time to 1st site 
lung metastasis (Log-Rank test, p-value=0.52). Although the difference was not statistically 
significant, median time to 1st site lung metastasis was shorter at about 2000 days (5.5 years) 
among non-recipients of PMRT compared to 2,300 days (6.3 years) among recipients (Figure 
2a).   
Discussion 
In this retrospective hospital-based case-control study of women with metastatic BC and 
contrary to findings from two prior epidemiologic studies,7,8 being a smoker at BC diagnosis did 
not appear to increase the odds of developing a 1st site lung metastasis in women diagnosed with 
BC. Furthermore, a smoking history did not shorten mean time to any site-specific metastasis 
(i.e., lung, liver, bone, brain). Ever smokers were however found to be more likely than never 
smokers to report a history of respiratory disease, and respiratory disease history was more 
common among women who received adjuvant PMRT than among others.  
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A larger proportion of women with 1st site lung metastasis than of other women in our 
sample had received adjuvant PMRT. In fact, women with metastatic BC who had received 
adjuvant PMRT were more than twice as likely to have 1st site lung metastasis than women who 
had not received adjuvant PMRT, even after adjusting for age at diagnosis and other adjuvant 
therapies. The majority of women with unilateral lung metastasis developed lung metastasis on 
the same side as the PMRT. The association was not statistically significant in a model that 
adjusted only for age at diagnosis and smoking history. The association of adjuvant PMRT with 
metastasis was specific to the lung. Furthermore, among women who developed a 1st site lung 
metastasis after their BC diagnosis, those who had received adjuvant PMRT developed their 1st 
site lung metastasis later than those who had not. We were not able to determine whether the 
lung metastasis was ipsilateral to the PMRT due sparse lung metastasis laterality data in the 
charts but this is an area that should be investigated further, especially given the positive results 
we report in our paper. 
A smaller proportion of women who received HRT prior to BC diagnosis than of non-
HRT recipients developed a 1st site lung metastasis.  Similarly, a chart review study had also 
reported that women who had not received HRT prior to BC diagnosis had significantly more 
lung and liver metastases than women who had received HRT.15  HRT is associated with SES, 
which is commonly associated with disparities in outcome.  
Another study had found that fewer women with than without lung metastases had 
received adjuvant hormonal therapy.7 The authors had speculated that hormonal therapy might 
not have been offered to, or might have been refused by, women who smoked because of the 
increased risk of thrombosis associated with both smoking and the use of tamoxifen. However, 
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we found no association between receipt of adjuvant hormonal therapy and occurrence of 1st site 
lung metastasis in our study, and no association between smoking status and hormonal therapy.  
We found no bias toward longer survival for cases versus controls; in fact mean follow-
up time was not statistically different between cases and controls. We further looked at the 
association between adjuvant PMRT and lung metastasis accounting for time to lung metastasis 
and censoring (i.e., loss to follow up or death) among women who developed a 1st site lung 
metastasis after their BC diagnosis. We observed that women who had received adjuvant PMRT 
developed their lung metastasis sooner than those who had not and that divergence in the 
survival curves occurred approximately 7 years after BC diagnosis. Prior studies focused on the 
risk of second lung primary as a consequence of adjuvant PMRT. In a published case-only 
design looking at women with BC and second lung primary,16  the mean latency period from 
primary diagnosis to second lung primary in women without PMRT was 9.7 years. In our study, 
we excluded from the analysis women with a single lung nodule that was not biopsy-confirmed 
to be linked to a breast primary, in order not to confuse lung metastasis with second lung 
primary. We understand that biopsy of a suspected metastatic growth is not systematic (only 
about a third of suspected lung metastatic cases were biopsied) but that the tissue most likely to 
be biopsied is often the site associated with the least invasive procedure.  
Our findings regarding smoking are based on a sample of women diagnosed with 
metastatic BC or with BC in stages I-III who subsequently developed metastasis; we compared 
women who developed lung metastasis as a 1st metastatic site to women who developed only 
non-lung metastases. However our analysis including both incident and prevalent cases also 
found no association between smoking and risk of lung metastasis in women with BC. The 
findings may have limited generalizability because they are based on a sample of women treated 
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for breast cancer at the CUMC, a patient population that comes mainly from New York, New 
Jersey and Connecticut and has a higher proportion of women self-reporting as Hispanic and a 
lower proportion of women self-reporting as Black than the general population of the United 
States. Other limitations of the current study include possible selection bias, such that patients 
with BC who presented with respiratory disease symptoms were potentially more likely to be 
imaged and diagnosed with 1st site lung metastasis than women without such symptoms. Receipt 
of adjuvant PMRT was significantly associated with a history of respiratory disease, and by 
extension may have been associated with earlier detection. To minimize confounding within this 
observational study, we collected information on known confounders (e.g., smoking, 
race/ethnicity, age at diagnosis, adjuvant chemotherapy) and adjusted for these in the analysis. 
We also selected study participants without knowing their exposure history and without 
information about known confounders. To minimize detection bias due to respiratory disease 
symptoms, imaging for disease progression would need to be performed as part of the routine 
clinical care after a diagnosis of BC and all sites would need to be imaged. However, current 
guidelines from the American Society of Clinical Oncology (ASCO) and the Breast Committee 
of the National Cancer Center Network (NCCN) around surveillance of asymptomatic BC 
survivors, recommend against routine surveillance for metastatic disease other than routine 
screening for locally recurrent tumor.17,18  
Another common source of bias in retrospective studies is potential recall bias affecting 
patient-reported exposures such as smoking history. Specifically, women with BC and a 1st site 
lung metastasis may have been more likely to recall or exaggerate a past smoking history than 
patients with metastases at other sites or felt the need to dissimulate the past history out of fear of 
judgement.  In our sample, women who identified as Hispanic were more likely than others to 
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report never smoking (40.6% vs. 26.8%). However, self-identified Hispanic women were also 
significantly more likely to be diagnosed with a lung metastasis as their 1st metastatic site. This 
finding suggests that factors other than smoking may affect the risk of lung metastasis among the 
Hispanic women in our catchment area.  However, given the social stigmatization of female 
smokers in the Hispanic community, it is possible that smoking was underreported by Hispanic 
patients. We had no means of verifying smoking histories reported by patients either in the 
questionnaire or in the medical record. However, we did not share with patients our hypothesis 
that smoking might affect risk of lung metastasis.   
Another limitation of this observational study is potential survival bias; exposed patients, 
such as smokers or women who received PMRT, may have been less likely than others to 
participate in this study if they died from causes unrelated to BC but related to the exposure (e.g., 
cardiovascular disease) or so soon after stage IV diagnosis or distant BC recurrence that they did 
not have the opportunity to consent to our study or fill out the study questionnaire. The potential 
systemic effect of smoking on BC metastasis must be distinguished from its direct effects on the 
lung, heart, and other organs. Moreover, in a case control study of between smoking and 
pulmonary metastatic disease in BC,7 72.4% of patients who smoked but only 31% of non-
smoking patients had metastatic disease involving sites other than the lung (mostly bone and 
liver). These effects of smoking may in part explain the lack of association we observed between 
smoking and occurrence of lung metastasis in women with BC. Information on smoking history 
or receipt of PMRT among CUMC patients who were diagnosed with BC during the period we 
studied but did not develop the relevant metastases was not available for us to assess the impact 
of this potential source of bias.  
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The potential effect of molecular factors on preferential site of metastasis in women with 
breast cancer should also be discussed. Breast cancer molecular subtypes have been associated 
with specific sites of metastasis.19 A nationwide cohort study found that BC for which the lung 
was the 1st site of distant metastasis often expressed either HER2 or EGFR (75.8%) receptors at 
the cell surface.20 Our study did not find a significant difference in hormonal status between 
women with and without lung metastasis as a 1st site. However, we did not power the study to 
measure the impact of hormonal status, and we did not assess EGFR status; these factors should 
be further investigated.   
Environmental factors, such as air pollution and chemical exposures, may also have an 
effect on site of metastasis, but we did not have data on such exposures. Although we recognize 
limitations in terms of sample size, this observational study was designed as an exploratory 
feasibility study. Given the signal we detected around adjuvant radiation therapy, we suggest 
collecting adjuvant treatment information in larger observational studies. A better understanding 
of the relationship between treatment factors and the site of metastasis has the potential to 
increase our understanding of the metastatic process. If we can develop better methods to 
identify women at high risk, or preventive or therapeutic measures against lung metastasis, we 
can reduce mortality from lung metastases.     
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Tables and Figures 
 
Table 1: Distribution of 183 Study Participants among Common Sites of Metastasis 
 Site First site* Time to Metastasis Follow-Up Time 
Site N (%) N (%) Mean (SD) years Mean (SD) years 
    Cases Controls p-value 
  Bone 145 (79.2) 109 (59.5) 7.6 (6.3) 8.05 ± 6.72 8.10 ± 6.30 0.66 
  Lung 102 (55.7) 70 (38.2)** 6.2 (5.0) 7.21 ± 5.36 8.66 ± 7.65 0.18 
  Liver 83 (45.4) 46 (25.1) 7.2 (5.7) 7.13 ± 5.43 8.83 ± 7.40 0.004 
  Brain 66 (36.1) 16 (8.7) 7.5 (6.9) 7.77 ± 6.79 8.22 ± 6.54 0.72 
# of sites 
  1 site 
  2 sites 
  3 sites 
















* In some patients, work-up uncovered multiple metastatic sites; if 2 sites were detected within a 
30-day period, we considered them to have occurred simultaneously. As a consequence, more 
than one site could have been considered as a 1st site. 
** Among the women who did not have a lung metastasis as the 1st site, 30 had a lung metastasis 











( 1st site met) 
No Lung Met 
 
P-value 
No. patients 151** 70 (46.3) 81 (53.7)  
Mean Age at Diagnosis (SD), 
years 
54.6 (13.9) 53.0 (13.7) 56.0 (14.0) 0.19 
Race / Ethnicity 
    White 
    Hispanic 
    Black 





















Stage at Diagnosis 
    I-III 














   Poorly differentiated 











Invasive Ductal Carcinoma 
Histology 
126 (83.4) 63 (90.0) 63 (77.8) 0.04 
Menopausal status 
   Pre- or peri-menopausal 












    ER positive 
    PR positive 

















Pre-diagnosis HRT 21 (13.9) 5 (7.1) 16 (19.7) 0.02 
Hormonal Birth Control 49 (32.4) 26 (37.1) 23 (28.4) 0.25 
Adjuvant Chemotherapy 112 (74.2) 57 (81.4) 55 (67.9) 0.06 
Adjuvant Hormone Therapy 112 (74.2) 49 (70.0) 63 (77.8) 0.28 
Adjuvant PMRT 62 (41.1) 36 (51.4) 26 (32.1) 0.02 
Side of PMRT in relation to Lung 
Met. 
    Contralateral 
    Ipsilateral 

















Mean PMRT Dose (cGy) (SD) 
    Lumpectomy (n=50) 














    None 
    BCT, SM, Lumpectomy 


















    Current 
    Former 



















    None 















*Missing or unknown values are not shown  
  
    20 years or more 28 (18.5) 12 (17.1) 16 (19.7)  
 
Severe Ever Smoking (≥10 pack 
years)  
38 (26.8) 15 (22.7) 23 (30.3) 0.31 
Respiratory Disease History 33 (22.9) 14 (21.5) 19 (24.0) 0.72 
T2DM 36 (25.0) 20 (30.3) 16 (20.5) 0.18 
BMI at Diagnosis  
    Normal 
    Overweight 





















Weight Loss/gain in 5 years Prior 
to Dx 
    >5% weight loss 
    Less than 5% change in weight 



















Table 3a: Characteristics of Women by Smoking History Status 
No (%)* Total Never smoker Ever Smoker P-value 
No. patients 183 101 (55.2%) 82 (44.8%)  
Race / Ethnicity 
    White 
    Hispanic 
    Black 





















Stage at Diagnosis 
    I-III 











Pre-diagnosis Hormone Replacement 
Therapy 
24 (13.1) 13 (12.9) 11 (13.4) 0.91 
Adjuvant Chemotherapy 140 (76.5) 78 (77.2) 62 (75.6) 0.80 
Adjuvant Hormonal Therapy 131 (71.6) 74 (73.3) 57 (69.5) 0.58 
Adjuvant Post-Mastectomy Radiation 
Therapy 
78 (42.6) 44 (43.5) 34 (41.5) 0.77 
Respiratory Disease History 43 (24.6) 18 (18.4) 25 (32.5) 0.03 
BMI at Diagnosis  
    Normal 
    Overweight 









   
31 (40.3) 
22 (28.6)  
24 (31.2) 
0.50 
Weight loss or gain within 5 years prior to 
diagnosis 
    >5% weight loss 
    Less than 5% change in weight 















    None 
    1st site 















    Parenchymal Nodules 













Lung metastasis (any order) 102 (55.7) 55 (54.5) 47 (57.3) 0.70 
Liver metastasis (any order) 83 (45.4) 47 (46.5) 36 (43.9) 0.72 
Bone metastasis (any order) 145 (79.2) 81 (80.2) 64 (78.0) 0.72 
Brain metastasis (any order) 66 (36.1) 39 (38.6) 27 (32.9) 0.42 
 
Table 3b: Mean Time to Metastatic Site by Smoking History Status 
Mean (standard deviation) Never smoker Ever Smoker t-test  
Mean time to lung 1812 (1697.2) 1898 (1913.3) 0.80 
Mean time to liver 1870 (1890.2) 2038 (2171.6) 0.70 
Mean time to bone 1683 (1724.3) 2315 (2741.3) 0.09 
Mean time to brain 1880 (256.9) 2907 (539.3) 0.06 





Table 4: Characteristics of Women Diagnosed in Stages I-III by Adjuvant PMRT Status  
N (%) Total PMRT No PMRT P-Value 
No. patients 133 78 (58.6) 55 (41.4)  
Age (Std Dev) 53.0 (13.8) 53.7 (13.0) 52.0 (15.0) 0.49 
Race / Ethnicity 
    White 
    Hispanic 
    Black 






















Adjuvant Chemotherapy  99 (74.4) 66 (84.6) 33 (60.0) 0.001 
Adjuvant Hormonal 
Therapy 
131 (71.6) 56 (71.8) 75 (71.4) 0.96 
Respiratory Disease 
History 
32 (25.0) 25 (33.3) 7 (13.2) 0.01 
BMI at Diagnosis  
    Normal 
    Overweight 















    Current 
    Former 
















    None 
    1st site 
















    Parenchymal Nodules 












Lung metastasis (any 
order) 
80 (60.1) 52 (66.7) 28 (50.9) 0.07 
Liver metastasis (any 
order) 
56 (42.1) 35 (44.9) 21 (38.2) 0.44 
Bone metastasis (any 
order) 
100 (75.2) 59 (75.6) 41 (74.5) 0.88 
Brain metastasis (any 
order) 
50 (37.6) 31 (39.7) 19 (34.5) 0.54 
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Table 5: Logistic regression to assess adjusted odds ratios (OR) for the relationship 
between smoking and/or PMRT and 1st site lung metastasis (women diagnosed in stages I-
IV) 
 
Variables Univariate Multivariate 
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  1.00 
[referent] 










   
  
 





  0.73 
[0.37;1.44] 





  0.32 
[0.14;0.73] 




















No consent given n=19
Bilateral BC n=13
Solitary lung metastsis n=9
Non-metastatic n=3
Non-Spanish or English speaking n=2
Male n=1




Figure 2a: Kaplan-Meier survival curves illustrating time (days) to 1st site lung metastasis 
by adjuvant PMRT status (women diagnosed in stages I-III) 
 





Time from BC diagnosis to lung metastasis by adjuvant PMRT 
status 116 observations, 46 censored                                                              






1 American Cancer Society. Cancer Facts & Figures 2015. Atlanta: American Cancer Society; 
2015. 
2 Brewster AM, Hortobagyi GN, et al. Residual Risk of Breast Cancer Recurrence 5 Years After 
Adjuvant Therapy. J Natl Cancer Inst 2008;100: 1179 – 1183. 
 
3  Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 
2001;411:375-379. 
4 Sihto H, Lundin J, et al.  Breast cancer biological subtypes and protein expression predict for the 
preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Research 2011, 
13:R87. 
 
5 Jain S, Fisher C, et al. Patterns of Metastatic Breast Cancer in Relation to Histological Type. Eur 
J Cancer 1993, Vol 29A, 15;2155-2157. 
 
6 Largillier R, Ferrero JM, et al. Prognostic Factors in 1038 Women with Metastatic Breast Cancer. 
Annals of oncology 2008; 19:2012-2019. 
 
7 Murin S, Inciardi J. Cigarette Smoking and The Risk of Pulmonary Metastasis from Breast 
Cancer. Chest 2001; 119:1635-1640. 
 
8 Scanlon EF, Suh O, Murthy SM, et al. Influence of smoking on the development of lung 
metastases from breast cancer. Cancer 1995; 75:2693-2699. 
 
9 Abrams JA, Lee PC, et al. Cigarette Smoking and Risk of Lung Metastasis from Esophageal 
Cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:2707-2713. 
 
10 Ford MB, Sigurdson AJ, Petrulis ES, et al. Effects of Smoking and Radiotherapy on Lung 
Carcinoma in Breast Carcinoma Survivors. Cancer 2003;98:1457–64. 
 
 
                                                     
61 
 
                                                                                                                                                                           
11 Kaufman EL1, Jacobson JS, Hershman DL, Desai M, Neugut AI. Effect of breast 
cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin 
Oncol. 2008;26(3):392-8.  
 
12 Neugut AI, Murray T, Santos J, Amols H, Hayes MK, Flannery JT, Robinson E. Increased risk 
of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer. 1994 Mar 
15;73(6):1615-20. 
 
13 Prochazka M, Granath F, Ekbom A, et al. Lung cancer risks in women with previous breast 
cancer. European Journal of Cancer (2002); 30:1520–1525. 
 
14 Quint LE, Park CH, et al. Solitary Pulmonary Nodules in Patients with Extrapulmonary 
Neoplasms. Radiology 2000; 217:257-261. 
 
15  Schuetz F, Diel IJ, Pueschel M, et al. Reduced incidence of distant metastases and lower 
mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am 
J Obstet Gynecol. 2007 Apr;196(4):342.e1-9. 
 
16 Prochazka M, Hall P, Gagliardi G, et al. Ionizing Radiation and Tobacco Use Increases the Risk 
of a Subsequent Lung Carcinoma in Women With Breast Cancer: Case-Only Design. Journal of 
Clinical Oncology 2005;Vol 23: 30:7467-7474.  
 
17 Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry 
NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE, American 
Society of Clinical Oncology. Breast cancer follow-up and management after primary treatment: 
American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 
Mar 1;31(7):961-5. 
 
18 Carlson RW, Allred DC, Anderson BO, et al. Invasive breast cancer. J Natl Compr Canc Netw. 
2011;9:136-222. 
 
19 Wang YK, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-
node-negative primary breast cancer. Lancet 2005, 365:671-679. 
 
20 Sihto H, Lundin J, et al.  Breast cancer biological subtypes and protein expression predict for 




IMPACT OF LIVER DISEASE ON LIVER METASTASIS 
IN WOMEN WITH BREAST CANCER 
 
 
Introduction ................................................................................................................................................. 63 
Materials and Methods ................................................................................................................................ 64 
Study Site: ............................................................................................................................................... 64 
Study Subjects:........................................................................................................................................ 64 
Study Recruitment: ................................................................................................................................. 64 
Data Collection: ...................................................................................................................................... 65 
Statistical Analysis: ................................................................................................................................. 67 
Results ......................................................................................................................................................... 68 
Discussion ................................................................................................................................................... 71 
Tables and Figures ...................................................................................................................................... 76 







 About 8-18% of breast cancer (BC) metastases are found in the liver.1,2  Because metastases 
replace or crowd out normal tissue, they interfere with the normal functions of affected organs and, if 
those functions are necessary to sustain life, such as, for the liver, detoxification and protein synthesis, 
metastases can cause death.3  Virtually nothing is known about the factors that cause or facilitate the 
development of breast cancer metastases in the liver, in preference to other organs or in general.  A 
better understanding of those factors might help us prevent such metastases.   
 Patients with primary cancer at organ/sites other than the breast may also develop liver 
metastases; the most common source organ for liver metastases is the large bowel.  In a study of patients 
who died with colorectal cancer (CRC), 95% were found to have liver metastases.4,5  A few studies have 
examined risk factors for such metastases.  In one study of 604 patients with resected CRC, 54 had 
synchronous liver metastases, including 52 of 541 (9.6%) with otherwise normal livers and 2 of 63 
(3.2%) with hepatic steatosis, the accumulation of excessive amounts of triglycerides and other fats 
inside liver cells (p=0=06).  Subsequent to CRC diagnosis, 12.1% of patients with otherwise normal 
livers but only 1.7% of those with hepatic steatosis developed liver metastases (p=0.004). In contrast, 
diabetes was positively associated with liver metastases in patients with CRC.6  Finally, among 133 
CRC patients, the risk ratio for liver metastasis among alcohol users vs. non-users was 2.57 (95% 
CI,1.43-4.36),  but risk was not associated with amounts of alcohol consumed,  nor did the patients 
appear to have “serious liver injury.”7   
We conducted a retrospective hospital-based case-control study of women with metastatic BC to 
assess whether a history of alcohol intake or chronic liver disease was associated with risk of developing 




Materials and Methods 
Study Site:   
 The study was conducted at the Columbia University Medical Center (CUMC), an academic 
medical center in which 200-300 patients per year are diagnosed with BC. The ethnically and 
socioeconomically diverse patient population comes mainly from New York, New Jersey and 
Connecticut.  The study was approved by the CUMC Institutional Review Board, and informed consent 
was obtained from all participants. 
 
Study Subjects:  
  The sampling frame was women who received treatment for metastatic BC at the CUMC 
between 2008 and 2013. Patient databases were screened to identify those with a) a histologically 
confirmed diagnosis of unilateral breast neoplasm with synchronous or metachronous metastasis; b) 
female gender; c) age at least 18 years; d) speaking Spanish or English; e) providing informed consent to 
participate in all aspects of the study; f) mentally competent as judged by medical study staff. For 
purposes of analysis, cases were defined as women diagnosed with metastasis to the liver as a 1st site of 
metastasis with or without metastasis to non-liver sites; metastasis was detected at diagnosis (prevalent 
or stage IV) or subsequent to BC diagnosis in stage I, II, or III (incident). Controls were women 
diagnosed with unilateral malignant breast neoplasm who had only non-liver metastases, detected at or 
after BC diagnosis. All women in our study population had at least one distant metastatic site.  
Study Recruitment:  
 Study subjects were patients of providers in the breast oncology clinic or breast surgeons, who 
were identified from the patient logs by recruiters from CUMC’s Herbert Irving Comprehensive Cancer 
Center (HICCC) Community & Ambulatory Research & Enrollment (CARE) shared resource. A CARE 
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recruiter contacted eligible patients in person, by phone or by mail prior to an office visit and invited 
them to participate in the HICCC Women with Breast Cancer Metastases (HICCC-WBCM) study. Three 
attempts were made to contact eligible patients by phone or mail before the patient was considered non-
responsive.  
Data Collection: 
 Questionnaire.  In the breast clinic, after obtaining informed consent, a trained interviewer 
administered the HICCC-WBCM questionnaire in a 60-minute face-to-face interview in the participant’s 
preferred language (English or Spanish).  The following variables were collected for all women using 
the HICCC-WBCM questionnaire:  
Personal alcohol history: The HICCC-WBCM questionnaire asked participants about their alcohol 
consumption by asking “Have you ever consumed alcoholic beverages such as coolers, beer, wine or 
liquor regularly (i.e. at least once a month for 6 months or more)?”. Those who responded “No” were 
classified as never drinkers, those who responded “Yes, I used to” were classified as former drinkers and 
those who answered “Yes”, we classified as current drinkers. 
Body Mass Index (BMI): at age 35, 5 years prior to and at BC diagnosis both as a continuous variable 
and using the following categories: 18.5-24.9=normal; 25-29.9=overweight and >30=obese. 
Record review.  Our HIPAA-certified research team collected data retrospectively from the 
patients’ records in the New York Presbyterian Hospital Electronic Medical Record (EMR) systems 
(WebCIS and CROWN), drawing on hospital admissions histories, imaging studies, laboratory data, 
pathology reports, and consultation notes.  
Breast Cancer: histologically confirmed diagnosis of metastatic or non-local recurrent unilateral breast 
neoplasm such that all cases and controls studied had metastatic disease either at diagnosis or upon 
recurrence. Like prior published studies of metastatic sites in women with BC8,9 ours included only 
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women with unilateral BC so that we could link the metastasis to a unique primary lesion and its distinct 
clinical characteristics. 
Type 2 Diabetes Mellitus (T2DM): we classified patients as diabetic or non-diabetic based on ICD-9 
coding. 
Metabolic syndrome: was adapted from the AHA/NHLBI 200510 Metabolic Syndrome Criteria using the 
following binary surrogate variables: obesity (BMI >30) in lieu of abdominal obesity; T2DM (ICD9 
coding) in lieu of fasting plasma glucose; hypertension (ICD-9 coding); hypercholesterolemia 
(HDL<50mg/dL or cholesterol>240mg/dL); or high triglycerides (>150mg/dL). If at least 3 of the 5 
criteria were present, metabolic syndrome was assumed to be present, when a value was missing we 
assumed it was 0.  
Chronic liver disease (CLD): based on review of the medical records where treating physicians recorded 
diagnosis through a combination of liver biopsy results, liver function test results, and CT scan or 
ultrasonography imaging suggesting the diagnosis of fatty liver, steatohepatitis, chronic hepatitis, 
cirrhosis, or liver necrosis.  
Liver metastasis: as interpreted by the clinician, whether or not it was biopsy-confirmed (women with 
metastatic BC rarely have a liver biopsy because it offers no survival advantage)11 and either present at 
diagnosis or detected during follow-up, was defined based on ultrasonography and/or computed 
tomography.12 Biopsy confirmation of liver metastasis was recorded where possible to exclude second 
primary liver cancer as well as non-malignant clinical manifestations 
Site of first or subsequent metastasis: determined by looking at imaging dates recorded in the medical 
chart upon which metastasis was first suspected or detected, dates across metastatic sites were 
compared. In some patients, work-up uncovered multiple metastatic sites; if 2 sites were detected within 
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a 30-day period, we considered them to have occurred simultaneously. As a consequence, more than one 
site could have been considered as a 1st site of metastasis. 
Follow-up time: time from BC diagnosis to death or last follow-up date due to study completion of loss 
to follow-up.  Some women died and others were lost to follow-up prior to the end of our study, but 
chart data were collected for all women until the end of the data collection phase in December 2014.  
 
Other Data:  
 The research team also collected data from the EMR on menopausal status, breast tumor 
characteristics (e.g., histology, grade, TNM stage, and molecular subtype), BC surgery and adjuvant 
treatment (i.e., chemotherapy, hormonal therapy or PMRT).   
Statistical Analysis: 
Categorical variables were analyzed using chi-square or Fisher’s exact tests. To assess linear 
trends in levels of categorical variables, the Mantel-Haenszel Chi-Square test statistic was used. 
Continuous variables were analyzed using two-sided student’s t-tests.  
Multivariate logistic regression models were developed to assess the adjusted association 
between history of chronic liver disease or alcohol intake and 1st site liver metastasis with adjustment for 
the potential confounding effects of the participant’s age, race/ethnicity, and stage of disease at time of 
BC diagnosis, BMI at diagnosis, metabolic syndrome, smoking history, adjuvant therapy or non-liver 




We conducted a Kaplan-Meier survival analysis to assess the relationship between a history of 
chronic liver disease and time from BC diagnosis to 1st site liver metastasis while accounting for 
censoring (i.e., loss to follow-up, study end, or patient death).  
Associations in which P<0.05 or the 95% confidence interval (95% CI) did not include the null 
value (1.00) were considered statistically significant. All analyses were performed using SAS statistical 
software, version 9.4; (SAS Institute; Cary, NC). 
 
Results 
Distribution of metastases  
We identified 183 women with histologically confirmed unilateral BC with metastases diagnosed 
between 1977 and 2013. Figure 1 describes the selection process for the study population. Among these 
women, 133 (72.7%) were diagnosed with BC at stages I to III, and subsequently developed metastatic 
disease, while 50 (27.3%) were diagnosed at stage IV. Eighty-three women (45.4% of the study sample) 
developed liver metastasis, which was biopsy confirmed in 19 (22.9%) women; 145 (79.2%) developed 
bone metastasis, 102 (55.7%) lung metastasis, and 66 (36.1%) brain metastasis. Only 46 of the women 
(25.1%) had a single metastatic site; 121 (66.1%) had 2 or 3 sites of metastasis, and the remaining 16 
(8.7%) had metastases in all 4 studied sites. The liver was the first metastatic site for 46 participants 
(25.1% of the sample or 55.4% of women with a liver metastasis); these 46 women constituted our case 
group.  The 100 women who developed only non-liver metastases constituted our control group (Table 
1). Follow-up time was 7.13 years for cases but 8.83 years for controls (p=0.004), and women initially 
diagnosed at stages I-III were followed for a longer average period (9.8 ± 6.9 years), than those 
diagnosed in stage IV (3.4 ± 2.3 years).  
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Characteristics of women diagnosed with liver as 1st metastasis vs. women with non-liver metastasis 
The mean age of our 146 study participants at BC diagnosis was 54.8 years; 77 women (52.7%) 
were post-menopausal at diagnosis. A larger proportion of cases than of controls self-identified as Black 
(21.7% vs. 10.0%). Women with a 1st site liver metastasis (cases) were less likely than controls to have 
been diagnosed in stages I-III (60.9% vs. 77.0%, p=0.04). Most cases and controls had invasive ductal 
carcinoma (91.3% vs. 81.0%, p=0.11). However, cases and controls did not differ in hormone receptor 
status (ER status, p=0.55; PR status, p=0.85; HER2 status, p=0.78) or tumor grade; 56.5% of cases and 
48.0% of controls had poorly differentiated tumors (p=0.62). A larger proportion of cases than controls 
had received adjuvant chemotherapy (86.9% vs. 75.0%, p=0.10), but fewer cases received adjuvant 
PMRT (32.6% vs. 43.0%, p = 0.23) or adjuvant hormone therapy (56.5% vs. 77.0%, p = 0.01). Cases did 
not differ from controls with respect to previous history of hormonal birth control (p = 0.10), hormone 
replacement therapy prior to BC diagnosis (p = 0.87), or types of BC surgery (p = 0.85). (Table 2) 
 
Relationship between alcohol intake or other lifestyle factors and liver as 1st metastasis in women with 
advanced BC 
A higher proportion of cases than controls reported alcohol intake concurrent with BC diagnosis 
but the difference was not statistically significant s (21.7% vs. 16.0%, p = 0.52), even after restricting 
the exposed category to those who reported at least 10 years of drinking and 3 drinks per week (p = 
0.83). (Table 2) We also found that women with and without chronic liver disease did not differ in 
alcohol intake (p = 0.37), even though women with no chronic liver disease history were slightly more 
likely to report never drinking alcohol (70.1% vs. 61.5%). (Table 3a) 
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Smoking history was not associated with having a 1st site liver metastasis (p = 0.98) nor was 
smoking history of at least 10 pack years (p = 0.88). About a quarter of both cases and controls reported 
having type 2 diabetes mellitus or met the criteria for metabolic syndrome (cases: 23.9% vs. controls: 
27.0%, p=0.69).  Fourteen cases (30.4%) and 21 controls (21.0%) were obese at BC diagnosis (p=0.21). 
(Table 2) 
Alcohol intake was not independently associated with odds of getting a 1st site liver metastasis 
(OR former = 0.62 [0.19;2.05]; OR current = 1.37 [0.56;3.34]), neither was metabolic syndrome (OR = 0.85 
[0.38;1.91]) or BMI at diagnosis (OR overweight = 1.03 [0.44;2.41]; OR obese = 1.67 [0.68;4.06]), or even 
smoking history (OR former = 0.96 [0.45;2.04]; OR current = 1.08 [0.33;3.49]). In a multivariate logistic 
regression model, we assessed the combined effect of alcohol intake and history of chronic liver disease 
on the odds of 1st site liver metastasis and found no increase from the impact of alcohol intake and 
chronic liver disease alone. (Table 4) 
 
Relationship between chronic liver disease and liver as 1st metastasis in women with advanced BC 
Of the 29 patients with chronic liver disease, 14 had fatty liver, 4 had non-alcoholic 
steatohepatitis, 9 had evidence of hepatitis B or C, and 5 had signs of liver cirrhosis; a handful of 
patients also had evidence of liver necrosis, liver transplant, or unspecified liver disease. Cases were 
more likely to have a history of chronic liver disease than controls (32.6% vs. 14.0%, p=0.009), and 
more likely to have fatty liver (17.4% vs. 6.0%, p=0.03). (Table 2) 
Women with a history of chronic liver disease were more likely to be diagnosed with stage IV 
BC than women without such a history (33.3% vs. 25.7%), but the difference was not statistically 
significant.  A history of chronic liver disease was also not associated with adjuvant chemotherapy, post-
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mastectomy radiation therapy, or hormonal therapy; type 2 diabetes mellitus, metabolic syndrome, or 
BMI at diagnosis. However, more women with than without chronic liver disease were obese at 
diagnosis (p = 0.05), or had gained at least 5% of their weight within the 5 years preceding BC diagnosis 
(p = 0.05).  (Table 3a)   
 Women who had a history of chronic liver disease were more likely to have a liver metastasis as 
a 1st metastatic site rather than a 2nd or 3rd site (38.5% vs 25.6%, p=0.02). We found that, history of 
chronic liver disease was not associated with metastasis to lung, brain, or bone. (Table 3a)  It was also 
not associated with mean time to site-specific metastasis, although mean time to brain metastasis was 
shorter for patients with than without a chronic liver disease history (1517 days vs. 2746 days, p = 0.05). 
(Table 3b) 
 In a multivariate logistic regression model, we found that women with metastatic BC who had a 
history of chronic liver disease were nearly three times as likely as women with no such history to have 
1st site liver metastasis (OR = 2.97 [1.29;6.86]). The association remained statistically significant after 
adjusting for alcohol (OR = 2.97 [1.27;6.94]) or BMI at diagnosis (OR = 2.78 [1.17;6.58]), presence of 




  In this retrospective hospital-based case-control study of women with metastatic BC, contrary to 
findings from prior epidemiologic studies of patients with CRC,7,11 we found that neither alcohol intake 
nor obesity increased the odds of developing a 1st site liver metastasis. We found however that a history 
of chronic liver disease was associated with a tripling of the odds of 1st site liver metastasis and that this 
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association remained significant after adjusting for age, alcohol intake, BMI at diagnosis, metabolic 
syndrome or adjuvant therapy. Our study focused on first metastases in women with BC, while prior 
published studies assessed any liver metastases in CRC patients.Error! Bookmark not defined.13,14,15 
oreover, while prior studies considered one liver disease diagnosis (i.e. chronic HBV infection, liver 
cirrhosis, and alcohol consumption), our study combined a range of conditions commonly grouped 
under the umbrella of non-alcoholic fatty liver disease (NAFLD), such as fatty liver, steatohepatitis, and 
chronic hepatitis, progressing to cirrhosis and eventually to liver failure and liver necrosis.16 One reason 
for including these various liver diseases is their common risk factors, such as obesity (prevalent in 30-
100% of patients with NAFLD), T2DM (prevalent in 10-75% of patients with NAFLD), and 
hyperlipidemia  (prevalent in 20-92% of patients with NAFLD).  Another reason for inclusion of 
NAFLD conditions is that they are commonly detected as fatty liver infiltrations that we were able to 
assess in our sample.17  
Follow-up time was longer for controls than for cases, and women who had a history of chronic 
liver disease developed the 1st site liver metastasis sooner than those who had no such history, 
suggesting that liver metastasis may have shortened the lives of affected patients. Indeed, liver 
metastases from breast cancer are known to be associated with a poor prognosis (median survival < 6 
months).3,18 
Our findings should be understood within the narrow context of a population of women either 
diagnosed with metastatic BC or diagnosed with BC in stages I-III who subsequently developed distant 
metastasis.  In addition, our findings apply only to women who developed liver metastases as a 1st 
metastatic site compared to women with only non-liver metastases. The findings may have limited 
generalizability because they are based on a sample of women treated for breast cancer at the CUMC, a 
patient population that comes mainly from New York, New Jersey and Connecticut and has a higher 
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proportion of women self-reporting as Hispanic and a lower proportion of women self-reporting as 
Black than the general population of the United States. Other limitations of the current study include 
possible detection bias, such that patients with BC who presented with known chronic liver disease may 
have been more likely to be imaged and diagnosed with 1st site liver metastasis than other women. We 
collected information on known confounders (e.g., smoking, race/ethnicity, age at diagnosis, BMI at 
diagnosis, metabolic syndrome) and adjusted for these in the analysis. We also selected study 
participants without knowing their status with respect to the exposure and known confounders. 
However, detection bias could be eliminated only if imaging for disease progression at all potential sites 
of metastasis were performed as part of routine clinical care after a diagnosis of BC. . Current guidelines 
from the American Society of Clinical Oncology (ASCO) and the Breast Committee of the National 
Cancer Center Network (NCCN) , discourage such routine surveillance of asymptomatic BC survivors 
for metastatic disease.19,20  
Another common pitfall of retrospective studies involving patient-reported exposures, such as 
alcohol intake history, is recall bias. Specifically, women with BC and a liver metastasis may have been 
more likely to recall or exaggerate their past alcohol intake history than women with only non-liver 
metastases. However, we did not share our hypothesis that alcohol may be associated with risk of liver 
metastasis with study participants.   
Another limitation of this observational study is the potential for survival bias as exposed (e.g., 
CLDH history) patients may have been less likely than others to participate in this study if they died 
from causes unrelated to BC but related to CLDH history or so soon after stage IV diagnosis or distant 
BC recurrence that they did not have the opportunity to consent to our study or fill out the study 
questionnaire. Information on alcohol history or CLDH of patients who met study inclusion criteria but 
did not participate was not available for us to assess the impact of this potential source of bias. We 
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understand that biopsy of a suspected metastatic growth is not systematic (only about a fifth of suspected 
liver metastatic cases were biopsied) but that the tissue most likely to be biopsied is often the site 
associated with the least invasive procedure. 
Finally, we were limited by our relatively small sample size, further reduced when we included 
as cases only those patients with 1st site liver metastasis. Given this limitation, our observational study 
was primarily exploratory.  However, we did detect a signal around history of chronic liver disease.  It 
encourages us to suggest conducting larger cohort studies to explore the temporal association between 
history of liver disease and risk of metastasis to the liver in women with breast cancer. If in the future a 
larger study confirms that liver disease is a predictor of liver metastases, if surveillance methods can be 
developed to improve early detection of such metastases, and if effective treatments become available 
for women in whom the metastasis is detected early, taking liver dysfunction into account may improve 
overall survival.  The CRC literature indicates that patients with liver metastases who had liver 
metastasectomy had better median overall survival than those who did not, after adjusting for number of 
comorbidities.21 The literature on liver metastasectomy in women with metastatic breast cancer is 
sparse.  Perhaps decisions regarding chemotherapy and biologic treatment of individuals with liver 
metastasis should also take the liver dysfunction into account.22  
The potential effect of molecular factors on preferential site of metastasis in women with breast 
cancer should also be discussed. Breast cancer molecular subtypes have been associated with specific 
sites of metastasis.23 A nationwide cohort study found that BC for which the lung was the 1st site of 
distant metastasis often expressed either HER2 or EGFR (75.8%) receptors at the cell surface.24 Our 
study did not find a significant difference in hormonal status between women with and without lung 
metastasis as a 1st site. However, we did not power the study to measure the impact of hormonal status, 
and we did not assess EGFR status; these factors should be further investigated.   
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Environmental factors, such as air pollution and chemical exposures, may also have an effect on site of 
metastasis, but we did not have data on such exposures. Although we recognize limitations in terms of 
sample size, this observational study was designed as an exploratory feasibility study. Given the signal 
we detected around adjuvant radiation therapy, we suggest collecting adjuvant treatment information in 
larger observational studies. A better understanding of the relationship between treatment factors and the 
site of metastasis has the potential to increase our understanding of the metastatic process. If we can 
develop better methods to identify women at high risk, or preventive or therapeutic measures against 
lung metastasis, we can reduce mortality from lung metastases.     
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Tables and Figures 
Table 1: Distribution of 183 Study Participants among Common Sites of Metastasis 
 Site First site* Time to Metastasis Follow-Up Time 
Site N (%) N (%) Mean (SD) years Mean (SD) years 
    Cases Controls p-value 
  Bone 145 (79.2) 109 (59.5) 7.6 (6.3) 8.05 ± 6.72 8.10 ± 6.30 0.66 
  Lung 102 (55.7) 70 (38.2) 6.2 (5.0) 7.21 ± 5.36 8.66 ± 7.65 0.18 
  Liver 83 (45.4) 46 (25.1)** 7.2 (5.7) 7.13 ± 5.43 8.83 ± 7.40 0.004 
  Brain 66 (36.1) 16 (8.7) 7.5 (6.9) 7.77 ± 6.79 8.22 ± 6.54 0.72 
# of sites 
  1 site 
  2 sites 
  3 sites 
















* In some patients, work-up uncovered multiple metastatic sites; if 2 sites were detected within a 30-day 
period, we considered them to have occurred simultaneously. As a consequence, more than one site 
could have been considered as a 1st site. 
** Among the women who did not have a liver metastasis as the 1st site, 27 had liver metastasis as a 2nd 












(1st site only) 
Other Met P-value 
No. patients 146 46 (25.1) 100 (54.6)  
Mean Age at Diagnosis (SD), years 54.8 (14.6) 54.5 (15.1) 55.0 (14.4) 0.84 
Race / Ethnicity 
    Black  
    White 
    Hispanic 





















Stage at Diagnosis 
    I-III 












   Poorly differentiated 











Invasive Ductal Histology 123 (84.2) 42 (91.3) 81 (81.0) 0.11 
Menopausal status 
   Pre- or peri-menopausal 












   ER positive 
   PR positive 

















Pre-diagnosis HRT 15 (10.3) 5 (10.9) 10 (10.0) 0.87 
Hormonal Birth Control 48 (32.9) 19 (41.3) 29 (29.0) 0.10 
Adjuvant Chemotherapy 115 (78.8) 40 (86.9) 75 (75.0) 0.10 
Adjuvant PMRT 58 (39.7) 15 (32.6) 43 (43.0) 0.23 
Adjuvant Hormone Therapy 103 (70.5) 26 (56.5) 77 (77.0) 0.01 
BC Surgery 
    None 
    BCT, SM, Lumpectomy 















    Current 
    Former 















Severe Smoking (≥10 pack years)  32 (34.4) 10 (33.3) 22 (34.9) 0.88 
Alcohol Intake  
    Current 
    Former 














Severe Alcohol (≥10 years; ≥3/week) 7 (7.5) 2 (6.7) 5 (7.9) 0.83 
Metabolic Syndrome 38 (26.0) 11 (23.9) 27 (27.0) 0.69 
Obese at Diagnosis 35 (24.0) 14 (30.4) 21 (21.0) 0.21 
T2DM 38 (26.0) 13 (28.3) 25 (25.0) 0.68 
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Liver Disease History* 29 (19.9) 15 (32.6) 14 (14.0) 0.009 
    Fatty Liver Disease 14 (9.6) 8 (17.4) 6 (6.0) 0.03 
    NASH 4 (2.7) 2 (4.3) 2 (2.0) 0.59 
    Hepatitis (alcoholic, B and C) 9 (6.2) 4 (8.7) 5 (5.0) 0.39 
    Cirrhosis 5 (3.4) 4 (8.7) 1 (1.0) 0.03 
* note some patients had more than one liver disease so the totals do not add up to 100% 
 
Table 3a: Characteristics of Women by Chronic Liver Disease History Status 
No (%)* Total No CLD CLD P-value 
No. patients 183 144 (78.7) 39 (21.3)  
Race / Ethnicity 
    White 
    Hispanic 
    Black 





















Stage at Diagnosis 
    I-III 











Adjuvant Chemotherapy 140 (76.5) 108 (75.0) 32 (82.0) 0.36 
Adjuvant Hormonal Therapy 131 (71.6) 102 (70.8) 29 (74.4) 0.19 
Adjuvant Post-Mastectomy Radiation Therapy 78 (42.6) 61 (42.4) 17 (43.6) 0.89 
Metabolic Syndrome 45 (24.6) 33 (22.9) 12 (30.8) 0.31 
Type 2 Diabetes Mellitus 46 (25.1) 32 (22.2) 14 (35.9) 0.08 
BMI at Diagnosis  
    Normal 
    Overweight 

















Weight loss or gain within 5 years prior to 
diagnosis 
    >5% weight loss 
    Less than 5% change in weight 

















Alcohol Intake  
    Current 
    Former 














Severe Alcohol (≥10 years; ≥3/week) 10 (8.8) 9 (9.9) 1 (4.3) 0.40 
Liver metastasis 
    None 
    1st site 














Liver metastasis (any order) 83 (45.4) 58 (40.3) 25 (64.1) 0.008 
Lung metastasis (any order) 102 (55.7) 77 (53.5) 25 (64.1) 0.24 
Bone metastasis (any order) 145 (79.2) 118 (81.9) 27 (69.2) 0.08 




Table 3b: Mean Time to Metastatic Site by Chronic Liver Disease History  
Mean (standard deviation) No CLDH CLDH t-test  
Mean time to lung 2139 (1756.2) 2029 (1438.2) 0.80 
Mean time to liver 2264 (1788.5) 2178 (1607.0) 0.87 
Mean time to bone 2345 (1944.4) 2011 (1856.1) 0.53 
Mean time to brain 2746 (2412.1) 1517 (1303.1) 0.05 






Table 4: Logistic regression to assess adjusted odds ratios (OR) for the relationship between 
history of chronic liver disease and 1st site liver metastasis in the full sample 
Variables Univariate Multivariate 















Race/Ethnicity      
   White 1.00 [referent]     
   Hispanic  0.92 [0.41;2.09]     
   Black  2.28 [0.81;6.42]     
Stage of BC Diagnosis       
   Stage I 1.00 [referent]     
   Stage II 1.56 [0.36;6.77]     
   Stage III 2.17 [0.51;9.23]     






Chronic Liver Disease      
    No 1.00 [referent] 1.00 [referent] 1.00 [referent] 1.00 [referent] 1.00 [referent] 








Alcohol Intake      
    No 1.00 [referent] 1.00 [referent]    












BMI at Diagnosis      
   Normal 1.00 [referent]  1.00 [referent]   








Smoking history      
    Never 1.00 [referent]     
    Former 0.96 [0.45;2.04]     
    Current 1.08 [0.33;3.49]     
Metabolic Syndrome       
   No 1.00 [referent]   1.00 [referent]  




Adj. PMRT       
   No 1.00 [referent]    1.00 [referent] 
   Yes 0.64 [0.31;1.33]    0.52 [0.24;1.16] 
Adj. Chemotherapy      
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   No 1.00 [referent]    1.00 [referent] 
   Yes 2.22 [0.84;5.86]    2.46 [0.86;7.09] 
Adj. Hormone 
Therapy 
   
 
 
   No 1.00 [referent]    1.00 [referent] 
   Yes 0.39 [0.18;0.82]    0.35 [0.16;0.77] 
Other Metastatic Sites      
   lung vs. non-lung 1.02 [0.50;2.06]     
   Bone vs. non-bone 0.64 [0.29;1.41]     
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Chapter 4: Conclusion remarks & future directions 
Summary of major findings 
 The overarching goal of this dissertation was to analyze the associations of select lifestyle 
(e.g., tobacco use, alcohol consumption) and clinical factors (e.g., post-mastectomy radiation 
therapy (PMRT), liver disease, body mass index, and diabetes) with metastases detected in the 
lung and/or the liver in women with advanced BC. Chapter 1 reviewed 18 published papers.  Ten 
papers dealt with associations between smoking and lung metastasis in women with BC and on 
the roles of obesity, hormone exposure (i.e., hormone replacement therapy prior to BC diagnosis 
and hormonal therapy post diagnosis), and PMRT in this association. Eight papers dealt with 
associations of hepatic steatosis or chronic hepatitis B infection, cirrhosis, and hyperglycemic 
and oxidative stress conditions or alcohol consumption with liver metastasis in CRC or BC 
patients.  
Chapter 2 examined whether smoking and / or post-mastectomy radiation therapy to the 
breast and/or the chest area were associated with an increased risk of 1st site lung metastasis in 
our sample of women with metastatic breast cancer.  
Chapter 3 aimed to assess whether a history of alcohol intake or chronic liver disease was 
associated with risk of developing a 1st site liver metastasis in our sample of women with 
metastatic BC.  
The main findings from our de-novo retrospective hospital-based prevalent case-control 




Chapter 1 principal findings 
Lung metastases 
Two observational studies in women with unilateral BC found a significant dose-
dependent association between a history of cigarette smoking and the development of lung 
metastasis. A history of smoking cigarettes was associated with a shorter time interval between 
BC diagnosis and lung metastasis detection. The association between exposure to tobacco smoke 
and mean metastatic lung metastases was corroborated by a mouse study. 
Obesity was found to be associated with larger axillary metastases and an increased 
number of lung metastases as well as with a biomarker of smoking-related lung inflammation in 
women with BC. Its association with both exposure and disease confirms the need to assess its 
impact on the primary relationship between smoking and lung metastasis.  
Two papers described associations of pulmonary and liver metastases in women with BC 
with hormonal therapy (e.g., tamoxifen or oophorectomy) which blocks estrogen’s effects on 
the breast, and with hormone replacement therapy (HRT) provided prior to BC diagnosis, 
which increases hormone levels. Although women who received HRT before BC diagnosis for at 
least one year exhibited fewer metastasis to the lung or liver, women who received adjuvant 
hormonal therapy after BC diagnosis to block the effects of hormones on the breast and reduce 
risk of recurrence, also had a lower risk of developing lung and liver metastasis as intended.  The 
apparent contradictory results should be investigated further along with the association between 
smoking status and hormonal therapy and the potentially confounding effects of socio-economic 
status and health awareness.   
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Post-mastectomy radiation therapy (PMRT) has been linked to an increased risk of 
second lung primary in women with BC. Published studies report an independent association 
between smoking and an increased risk of second primary lung cancer in women with BC, this 
risk was sharply increased in smokers who received PMRT after a diagnosis of BC, especially in 
the ipsilateral lung. This elevated risk was detectable 10 or more years after BC diagnosis and 
PMRT treatment, with a higher mean latency of ipsilateral lung cancers over contralateral lung 
cancers. The impact of smoking history and PMRT in women diagnosed with BC on the 
occurrence of lung metastasis should be investigated alongside the mean latency from BC 
diagnosis to lung metastasis development. 
Liver metastases 
Because the literature on liver metastases in BC is sparse, we reviewed the literature on liver 
metastases in CRC to generate hypotheses regarding the role of lifestyle factors and clinical 
variables in metastasis to the liver among BC patients.  
Two papers assessed the association between hepatic steatosis or chronic hepatitis B 
virus (HBV) infection and liver metastasis in CRC patients. Both hepatic steatosis and chronic 
hepatitis B in such patients appeared to be associated with reduced risk of liver metastasis. 
Hepatic steatosis was associated with improved recurrence-free survival due to a decrease in the 
number of intrahepatic metastases; this association was observed only in non-obese patients. In 
CRC patients with hepatic steatosis and chronic HBV, liver damage had no impact on the 
association. Two papers described the association between cirrhosis and liver metastases in 
CRC patients and suggested that CRC rarely metastasizes to the cirrhotic liver. 
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Three laboratory studies reported on the association between hyperglycemic conditions 
or oxidative stress and liver metastasis in CRC or BC models and found that hyperglycemic 
conditions may lead to A-II activation in CRC cells and to an increase in the size and number of 
liver metastases. Lipid alteration under conditions of oxidative stress was similarly associated 
with an increased number of metastatic nodules in the lung and liver in vivo BC models.  
We found one publication looking at the association between alcohol consumption and 
liver metastasis in patients with CRC found that alcohol consumption was found to be a 
significant and independent risk factor for liver metastasis in CRC patients, especially with 
synchronous liver metastasis. 
 
Chapter 2 principal findings 
Our retrospective hospital-based case-control study followed 183 women with 
histologically confirmed unilateral BC and metastases for an average of 8 years. Among the 133 
women initially diagnosed at stages I-III, the mean time to a lung metastasis was 6.2 years. For 
70 out of the 102 women who developed a lung metastasis, lung was the 1st metastatic site. 
Unlike two prior epidemiologic studies, ours did not confirm our main hypothesis of an 
association between smoking history and an increased risk of developing 1st site lung metastasis 
in women with BC. Indeed, in our multivariable logistic regression model, neither current nor 
past smoking was an independent risk factor for 1st site lung metastasis (OR former =1.15 
[0.58;2.29];  OR current = 0.51 [0.15;1.79). A history of respiratory disease was also not 
distributed differentially among cases and controls (p RDH = 0.72). Furthermore, smoking history 
was not associated with mean time to site-specific metastasis (p lung = 0.80; p liver = 0.70; p Bone = 
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0.09; p Brain = 0.06). Other lifestyle factors we considered, such as BMI at diagnosis, and a 5% 
weight loss or weight gain within 5 years of BC diagnosis, were similarly not associated with 
having a 1st site lung metastasis (p BMI = 0.15; p weight change = 0.40). 
Looking at the impact of treatment factors on the occurrence of lung metastasis, we found 
that among women diagnosed at stages I–IV, the odds of developed a 1st site lung metastasis 
more than doubled in women who received adjuvant PMRT (OR crude = 2.24 [1.15;4.34]) and 
remained statistically significant after adjusting for age and other adjuvant therapies (OR adj = 
2.08 [1.06;4.08]). When we adjusted for smoking history however, the relationship was not 
statistically significant. Using survival analysis to assess overall time to 1st site lung metastasis, 
we observed that among women who developed a lung metastasis, those who received adjuvant 
PMRT developed metastasis sooner than those who did not receive PMRT (Log-Rank test p-
value = 0.06) and that the effect of adjuvant PMRT was exerted approximately 6.8 years after 
BC diagnosis (note that adjuvant PMRT was provided soon after BC diagnosis for most women).  
Consistent with the findings of a chart review study, a significantly smaller proportion of 
our study participants who received HRT prior to BC diagnosis developed a 1st site lung 
metastasis.  However, unlike a prior report that fewer women with than without lung metastases 
had received adjuvant hormonal therapy, we found no association between receipt of adjuvant 
hormonal therapy and occurrence of 1st site lung metastasis. The authors had speculated that 
hormonal therapy might not have been offered to, or might have been refused by, women who 
smoked because of the increased risk of thrombosis associated with both smoking and the use of 
tamoxifen. However, we found no association between smoking status and hormonal therapy.  
Taken together, these findings suggested that lifestyle factors such as smoking history or 
BMI at diagnosis might not affect the likelihood of 1st site lung metastasis in women with 
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metastatic BC. We did find that receipt of adjuvant PMRT increased the odds of 1st site lung 
metastases and that these would occur sooner in women who had received PMRT than in women 
who had not. 
 
Chapter 3 principal findings 
Among the 133 women initially diagnosed at stages I-III, the mean time to a 1st site liver 
metastasis was 7 years and was significantly shorter than for women who did not have a liver 
metastasis. The liver was the first metastatic site for 46 study participants or 55.4% of women 
with a liver metastasis, these 46 women constituted our case group. 
 Contrary to findings from prior epidemiologic studies, risk for a 1st site liver metastasis 
was not associated with alcohol intake or obesity but was associated with a history of chronic 
liver disease, and that association remained significant in a model adjusted for BMI at diagnosis, 
metabolic syndrome or adjuvant therapy. However, our findings may have been different from 
those of prior published studies because they assessed any liver metastasis in CRC patients, 
while our study looked at the association of chronic liver disease history and odds of liver 
metastasis in women with BC.  Moreover, while prior studies defined the exposure as one liver 
disease diagnosis (chronic HBV infection, liver cirrhosis, or alcohol consumption), our exposure 
variable combined a range of conditions commonly grouped under the umbrella of non-alcoholic 
fatty liver disease (NAFLD), such as fatty liver, steatohepatitis, and chronic hepatitis, 
progressing to cirrhosis and eventually to liver failure and liver necrosis.  One reason for 
including these various liver diseases is their common risk factors, such as obesity (prevalent in 
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30-100% of patients with NAFLD), T2DM (prevalent in 10-75% of patients with NAFLD), and 
hyperlipidemia  (prevalent in 20-92% of patients with NAFLD).   
Women who had a history of chronic liver disease developed the 1st site liver metastasis 
sooner than those who had no such history. Liver metastases from breast cancer are known to be 
associated with a poor prognosis but our current study did not report a survival disadvantage of 
having a history of chronic liver disease. 
Taken together, these findings suggested that lifestyle factors such as alcohol intake or 
obesity might not affect the likelihood of 1st site liver metastasis in women with metastatic BC. 
We did find that a history of chronic liver disease significantly increased the odds of 1st site liver 
metastasis, which would occur sooner in women with than without such a history.  
 
Study Limitations 
Our findings are based on our sample of women diagnosed with metastatic BC or 
diagnosed with BC in stages I-III who subsequently developed metastasis.  In addition, our 
findings apply only to women who developed lung or liver metastases as a 1st metastatic site 
compared to women who developed other metastases, but not to women who developed no 
metastases in a comparable follow-up period. 
Other limitations of our study include possible detection bias, such that patients with BC 
who presented with respiratory disease symptoms or known liver disease may have been more 
likely to be scrutinized more intensively, via imaging at the relevant organ site, than other 
patients. Although we collected information on known confounders and adjusted for these in the 
analysis and recruited our study participants without knowledge of their exposure and 
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confounder status, we may not have eliminated the bias. Only systematic imaging of all potential 
metastatic sites, performed as part of the routine clinical care after a diagnosis of BC, could 
eliminate the possibility of detection bias.   However, current guidelines from the American 
Society of Clinical Oncology (ASCO) and the Breast Committee of the National Cancer Center 
Network (NCCN) around surveillance of asymptomatic BC survivors, discourage routine 
surveillance for distant metastatic disease.   
The study makes the assumption that smoking status at diagnosis did not change over the 
6 years of follow-up.  We did not attempt to collect data on smoking status during follow-up, 
although increased smoking or smoking cessation after BC diagnosis might have affected the 
odds of 1st site lung metastasis among patients diagnosed in stages I-III. We also made the 
assumption that chronic liver disease preceded liver metastasis.  Although liver metastasis seems 
unlikely to cause fatty liver, steatohepatitis, chronic hepatitis, cirrhosis, or liver necrosis, a 
longitudinal study should collect dates of liver disease diagnosis as well as results of liver 
function tests (i.e. ALT, AST) prior to liver metastasis. Finally, when assessing 1st site of 
metastasis, we made the assumption that metastases grow at the same rate in all the distant 
organs we considered (i.e., bone, brain, lung and liver) and that current detection methods for 
each metastatic site would allow for detection of metastasis in the same stage of development.   
Another common pitfall of retrospective studies involving patient-reported exposures, 
such as smoking history, is recall bias. Specifically, women with BC and a 1st site lung 
metastasis may have been more likely to recall or exaggerate a past smoking history.   However, 
we did not share our hypotheses this bias.   
Our study also may be subject to survival bias if exposed patients, such as smokers, 
women who received PMRT, or women with chronic liver disease, maybe because they were 
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sicker, were less likely than women without those conditions to participate.  If they died sooner 
after stage IV diagnosis or post-diagnosis detection of distant metastases, they would have had 
less opportunity to consent to our study and to fill out the study questionnaire. Information on 
exposure history of patients who met study inclusion criteria but did not participate was not 
available for us to assess the impact of this potential source of bias.  
Finally, our study is limited by small sample size, but we view it as an exploratory 
feasibility study, and we view its limited findings as hypotheses requiring further testing. Given 
the signals we detected around adjuvant radiation therapy and chronic liver disease, we suggest 
collecting adjuvant treatment or relevant comorbid information in larger cohort studies. A better 
understanding of the relationship between these factors and the sites of metastasis has the 
potential to increase our understanding of the metastatic process. If we can find ways to identify 
women at high risk of metastatic disease, or develop preventive or therapeutic measures against 
lung or liver metastasis, we can hope to reduce mortality from metastases.     
